You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRisperidone
Accession NumberDB00734  (APRD00187)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionRisperidone, a benzisoxazole derivative, is an atypical antipsychotic drug with high affinity for 5-hydrotryptamine (5-HT) and dopamine D2 receptors. It is used primarily in the management of schizophrenia, inappropriate behavior in severe dementia and manic episodes associated with bipolar I disorder. Risperidone is effective for treating the positive and negative symptoms of schizophrenia owing to its affinity for its “loose” binding affinity for dopamine D2 receptors and additional 5-HT antagonism compared to first generation antipsychotics, which are strong, non-specific dopamine D2 receptor antagonists.
Structure
Thumb
Synonyms
Risperdal
risperdone
Risperidona
Risperidonum
Risperin
Rispolept
Rispolin
Sequinan
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Risperidonetablet1 mgoralActavis Pharma Company2006-07-05Not applicableCanada
Act Risperidonetablet2 mgoralActavis Pharma Company2006-07-05Not applicableCanada
Act Risperidonetablet0.25 mgoralActavis Pharma Company2006-07-05Not applicableCanada
Act Risperidonetablet3 mgoralActavis Pharma Company2006-07-05Not applicableCanada
Act Risperidonetablet0.5 mgoralActavis Pharma Company2006-07-05Not applicableCanada
Act Risperidonetablet4 mgoralActavis Pharma Company2006-07-05Not applicableCanada
Ag-risperidonetablet0.50 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidonetablet4.0 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidonetablet1.0 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidonetablet2.0 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidonetablet3.0 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-risperidonetablet0.25 mgoralAngita Pharma Inc.Not applicableNot applicableCanada
Ava-risperidonetablet1.0 mgoralAvanstra Inc2011-08-182014-08-21Canada
Ava-risperidonetablet2.0 mgoralAvanstra Inc2011-08-182014-08-21Canada
Ava-risperidonesolution1 mgoralAvanstra Inc2011-10-112014-08-21Canada
Ava-risperidonetablet3.0 mgoralAvanstra Inc2011-08-182014-08-21Canada
Ava-risperidonetablet0.25 mgoralAvanstra Inc2011-08-182014-08-21Canada
Ava-risperidonetablet4.0 mgoralAvanstra Inc2011-08-182014-08-21Canada
Ava-risperidonetablet0.5 mgoralAvanstra Inc2011-08-182014-08-21Canada
Dom-risperidonetablet2.0 mgoralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidonetablet0.25 mgoralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidonetablet3.0 mgoralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidonetablet0.5 mgoralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidonetablet4.0 mgoralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidonetablet1.0 mgoralDominion Pharmacal2006-08-08Not applicableCanada
Dom-risperidonesolution1 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-risperidone ODTtablet (orally disintegrating)0.5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-risperidone ODTtablet (orally disintegrating)1 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-risperidone ODTtablet (orally disintegrating)2 mgoralDominion PharmacalNot applicableNot applicableCanada
Ipg-risperidonetablet0.25 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-risperidonetablet1 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-risperidonetablet4 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-risperidonetablet2 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-risperidonetablet3 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-risperidonetablet0.5 mgoralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-risperidonetablet2.0 mgoralJamp Pharma Corporation2010-12-23Not applicableCanada
Jamp-risperidonetablet0.25 mgoralJamp Pharma Corporation2010-12-23Not applicableCanada
Jamp-risperidonetablet3.0 mgoralJamp Pharma Corporation2010-12-23Not applicableCanada
Jamp-risperidonetablet0.50 mgoralJamp Pharma Corporation2010-12-23Not applicableCanada
Jamp-risperidonetablet4.0 mgoralJamp Pharma Corporation2010-12-23Not applicableCanada
Jamp-risperidonesolution1 mgoralJamp Pharma CorporationNot applicableNot applicableCanada
Jamp-risperidonetablet1.0 mgoralJamp Pharma Corporation2010-12-23Not applicableCanada
Mar-risperidonetablet1.0 mgoralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mar-risperidonetablet2.0 mgoralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mar-risperidonetablet0.25 mgoralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mar-risperidonetablet3.0 mgoralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mar-risperidonetablet0.50 mgoralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mar-risperidonetablet4.0 mgoralMarcan Pharmaceuticals Inc2013-04-17Not applicableCanada
Mint-risperidontablet1.0 mgoralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mint-risperidontablet2.0 mgoralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mint-risperidontablet0.25 mgoralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mint-risperidontablet3.0 mgoralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mint-risperidontablet0.50 mgoralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mint-risperidontablet4.0 mgoralMint Pharmaceuticals Inc2011-01-05Not applicableCanada
Mylan-risperidonetablet0.25 mgoralMylan Pharmaceuticals Ulc2006-07-05Not applicableCanada
Mylan-risperidonetablet3.0 mgoralMylan Pharmaceuticals Ulc2006-07-05Not applicableCanada
Mylan-risperidonetablet0.50 mgoralMylan Pharmaceuticals Ulc2006-07-05Not applicableCanada
Mylan-risperidonetablet4.0 mgoralMylan Pharmaceuticals Ulc2006-07-05Not applicableCanada
Mylan-risperidonetablet1.0 mgoralMylan Pharmaceuticals Ulc2006-07-05Not applicableCanada
Mylan-risperidonetablet2.0 mgoralMylan Pharmaceuticals Ulc2006-07-05Not applicableCanada
Mylan-risperidone ODTtablet (orally disintegrating)0.5 mgoralMylan Pharmaceuticals Ulc2013-10-24Not applicableCanada
Mylan-risperidone ODTtablet (orally disintegrating)4 mgoralMylan Pharmaceuticals Ulc2013-10-24Not applicableCanada
Mylan-risperidone ODTtablet (orally disintegrating)1 mgoralMylan Pharmaceuticals Ulc2013-10-24Not applicableCanada
Mylan-risperidone ODTtablet (orally disintegrating)2 mgoralMylan Pharmaceuticals Ulc2013-10-24Not applicableCanada
Mylan-risperidone ODTtablet (orally disintegrating)3 mgoralMylan Pharmaceuticals Ulc2013-10-24Not applicableCanada
Nu-risperidonetablet4 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-risperidonetablet1 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-risperidonetablet2 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-risperidonetablet0.25 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-risperidonetablet3 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-risperidonetablet0.5 mgoralNu Pharm IncNot applicableNot applicableCanada
PHL-risperidonetablet0.5 mgoralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidonetablet4.0 mgoralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidonetablet1.0 mgoralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidonetablet2.0 mgoralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidonetablet0.25 mgoralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidonetablet3.0 mgoralPharmel Inc2006-08-09Not applicableCanada
PHL-risperidone ODTtablet (orally disintegrating)0.5 mgoralPharmel IncNot applicableNot applicableCanada
PHL-risperidone ODTtablet (orally disintegrating)1 mgoralPharmel IncNot applicableNot applicableCanada
PHL-risperidone ODTtablet (orally disintegrating)2 mgoralPharmel IncNot applicableNot applicableCanada
PMS-risperidonetablet2.0 mgoralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidonetablet3.0 mgoralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidonetablet0.25 mgoralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidonetablet4.0 mgoralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidonetablet0.5 mgoralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidonesolution1 mgoralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidonetablet1.0 mgoralPharmascience Inc2006-07-05Not applicableCanada
PMS-risperidone ODTtablet (orally disintegrating)3 mgoralPharmascience Inc2011-12-16Not applicableCanada
PMS-risperidone ODTtablet (orally disintegrating)2 mgoralPharmascience Inc2007-03-13Not applicableCanada
PMS-risperidone ODTtablet (orally disintegrating)4 mgoralPharmascience Inc2011-12-16Not applicableCanada
PMS-risperidone ODTtablet (orally disintegrating)0.5 mgoralPharmascience Inc2007-03-13Not applicableCanada
PMS-risperidone ODTtablet (orally disintegrating)1 mgoralPharmascience Inc2007-03-13Not applicableCanada
Pro-risperidonetablet2.0 mgoralPro Doc Limitee2008-07-09Not applicableCanada
Pro-risperidonetablet0.25 mgoralPro Doc Limitee2008-07-09Not applicableCanada
Pro-risperidonetablet3.0 mgoralPro Doc Limitee2008-07-09Not applicableCanada
Pro-risperidonetablet0.5 mgoralPro Doc Limitee2008-07-09Not applicableCanada
Pro-risperidonetablet4.0 mgoralPro Doc Limitee2008-07-09Not applicableCanada
Pro-risperidonetablet1.0 mgoralPro Doc Limitee2008-07-09Not applicableCanada
Q-risperidonetablet0.5 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidonetablet4 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidonetablet1 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidonetablet0.25 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidonetablet2 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-risperidonetablet3 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ran-risperidonetablet4.0 mgoralRanbaxy Pharmaceuticals Canada Inc.2009-10-22Not applicableCanada
Ran-risperidonetablet0.5 mgoralRanbaxy Pharmaceuticals Canada Inc.2009-10-22Not applicableCanada
Ran-risperidonetablet2 mgoralRanbaxy Pharmaceuticals Canada Inc.2006-06-302012-06-13Canada
Ran-risperidonetablet0.25 mgoralRanbaxy Pharmaceuticals Canada Inc.2006-06-302012-06-13Canada
Ran-risperidonetablet1.0 mgoralRanbaxy Pharmaceuticals Canada Inc.2009-10-22Not applicableCanada
Ran-risperidonetablet3 mgoralRanbaxy Pharmaceuticals Canada Inc.2006-06-302012-06-13Canada
Ran-risperidonetablet0.5 mgoralRanbaxy Pharmaceuticals Canada Inc.2006-06-302012-06-13Canada
Ran-risperidonetablet2.0 mgoralRanbaxy Pharmaceuticals Canada Inc.2009-10-22Not applicableCanada
Ran-risperidonetablet4 mgoralRanbaxy Pharmaceuticals Canada Inc.2006-06-302012-06-13Canada
Ran-risperidonetablet1 mgoralRanbaxy Pharmaceuticals Canada Inc.2006-06-302012-06-13Canada
Ran-risperidonetablet0.25 mgoralRanbaxy Pharmaceuticals Canada Inc.2009-10-22Not applicableCanada
Ran-risperidonetablet3.0 mgoralRanbaxy Pharmaceuticals Canada Inc.2009-10-22Not applicableCanada
Ratio-risperidonetablet3.0 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Ratio-risperidonetablet0.25 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Ratio-risperidonetablet4.0 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Ratio-risperidonetablet0.5 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Ratio-risperidonetablet1.0 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Ratio-risperidonetablet2.0 mgoralRatiopharm Inc Division Of Teva Canada Limited2006-07-052015-10-26Canada
Risperdaltablet3 mg/1oralCardinal Health1993-12-29Not applicableUs
Risperdaltablet0.25 mgoralJanssen Inc1999-09-17Not applicableCanada
Risperdaltablet1 mg/1oralRebel Distributors Corp1993-12-29Not applicableUs
Risperdaltablet1 mg/1oralPd Rx Pharmaceuticals, Inc.1993-12-29Not applicableUs
Risperdalsolution1 mg/mLoralJanssen Pharmaceuticals, Inc.1996-06-10Not applicableUs
Risperdaltablet3 mgoralJanssen Inc1993-12-31Not applicableCanada
Risperdaltablet3 mg/1oralJanssen Pharmaceuticals, Inc.1993-12-29Not applicableUs
Risperdaltablet.5 mg/1oralREMEDYREPACK INC.2013-05-072016-04-05Us
Risperdaltablet1 mg/1oralJanssen Pharmaceuticals, Inc.1993-12-29Not applicableUs
Risperdaltablet.5 mg/1oralCardinal Health1993-12-29Not applicableUs
Risperdaltablet0.5 mgoralJanssen Inc1999-09-17Not applicableCanada
Risperdaltablet3 mg/1oralRebel Distributors Corp1993-12-29Not applicableUs
Risperdaltablet4 mg/1oralPd Rx Pharmaceuticals, Inc.1993-12-29Not applicableUs
Risperdaltablet4 mgoralJanssen Inc1993-12-31Not applicableCanada
Risperdaltablet5 mgoralJanssen Inc1999-05-282009-08-05Canada
Risperdaltablet1 mg/1oralCardinal Health1993-12-29Not applicableUs
Risperdaltablet.25 mg/1oralJanssen Pharmaceuticals, Inc.1993-12-29Not applicableUs
Risperdaltablet2 mg/1oralJanssen Pharmaceuticals, Inc.1993-12-29Not applicableUs
Risperdaltablet.5 mg/1oralREMEDYREPACK INC.2013-05-062016-04-05Us
Risperdaltablet2 mgoralJanssen Inc1993-12-31Not applicableCanada
Risperdaltablet.5 mg/1oralPd Rx Pharmaceuticals, Inc.1993-12-29Not applicableUs
Risperdaltablet4 mg/1oralJanssen Pharmaceuticals, Inc.1993-12-29Not applicableUs
Risperdaltablet2 mg/1oralCardinal Health1993-12-29Not applicableUs
Risperdaltablet.5 mg/1oralJanssen Pharmaceuticals, Inc.1993-12-29Not applicableUs
Risperdaltablet1 mgoralJanssen Inc1993-12-31Not applicableCanada
Risperdaltablet2 mg/1oralPd Rx Pharmaceuticals, Inc.1993-12-29Not applicableUs
Risperdal ConstakitJanssen Pharmaceuticals, Inc.2003-10-29Not applicableUs
Risperdal Constapowder for suspension, sustained-release; kit37.5 mgintramuscularJanssen Inc2004-09-08Not applicableCanada
Risperdal Constapowder for suspension, sustained-release; kit12.5 mgintramuscularJanssen Inc2007-10-24Not applicableCanada
Risperdal ConstakitJanssen Pharmaceuticals, Inc.2003-10-29Not applicableUs
Risperdal Constapowder for suspension, sustained-release; kit50 mgintramuscularJanssen Inc2004-09-08Not applicableCanada
Risperdal ConstakitJanssen Pharmaceuticals, Inc.2003-10-29Not applicableUs
Risperdal Constapowder for suspension, sustained-release; kit25 mgintramuscularJanssen Inc2004-09-08Not applicableCanada
Risperdal ConstakitJanssen Pharmaceuticals, Inc.2003-10-29Not applicableUs
Risperdal M-tabtablet, orally disintegrating4 mg/1oralJanssen Pharmaceuticals, Inc.2003-04-02Not applicableUs
Risperdal M-tabtablet (orally disintegrating)2 mgoralJanssen Inc2003-07-27Not applicableCanada
Risperdal M-tabtablet, orally disintegrating.5 mg/1oralJanssen Pharmaceuticals, Inc.2003-04-02Not applicableUs
Risperdal M-tabtablet, orally disintegrating1 mg/1oralJanssen Pharmaceuticals, Inc.2003-04-02Not applicableUs
Risperdal M-tabtablet, orally disintegrating3 mg/1oralJanssen Pharmaceuticals, Inc.2003-04-02Not applicableUs
Risperdal M-tabtablet (orally disintegrating)0.5 mgoralJanssen Inc2003-07-27Not applicableCanada
Risperdal M-tabtablet (orally disintegrating)3 mgoralJanssen Inc2005-06-20Not applicableCanada
Risperdal M-tabtablet (orally disintegrating)1 mgoralJanssen Inc2003-07-27Not applicableCanada
Risperdal M-tabtablet (orally disintegrating)4 mgoralJanssen Inc2005-06-20Not applicableCanada
Risperdal M-tabtablet, orally disintegrating2 mg/1oralJanssen Pharmaceuticals, Inc.2003-04-02Not applicableUs
Risperdal Oral Solutionsolution1 mgoralJanssen Inc1998-03-04Not applicableCanada
Risperidonetablet1 mgoralSanis Health Inc2010-10-21Not applicableCanada
Risperidonetablet0.5 mgoralMeliapharm Inc2009-02-262014-06-25Canada
Risperidonetablet1 mg/1oralA S Medication Solutions1993-12-29Not applicableUs
Risperidonesolution1 mg/mLoralJanssen Pharmaceutical, Inc.1996-06-10Not applicableUs
Risperidonetablet4.0 mgoralMeliapharm Inc2009-02-262014-06-25Canada
Risperidonetablet2.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Risperidonetablet1 mg/1oralJanssen Pharmaceutical, Inc.1993-12-29Not applicableUs
Risperidonetablet1 mg/1oralCardinal Health1993-12-29Not applicableUs
Risperidonetablet2 mgoralSanis Health Inc2010-10-21Not applicableCanada
Risperidonetablet1.0 mgoralMeliapharm Inc2009-02-262014-06-25Canada
Risperidonetablet0.25 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Risperidonetablet3.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Risperidonetablet2 mg/1oralJanssen Pharmaceutical, Inc.1993-12-29Not applicableUs
Risperidonetablet2 mg/1oralCardinal Health1993-12-29Not applicableUs
Risperidonetablet0.25 mgoralSanis Health Inc2010-10-21Not applicableCanada
Risperidonetablet0.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Risperidonetablet.25 mg/1oralJanssen Pharmaceutical, Inc.1993-12-29Not applicableUs
Risperidonetablet3 mgoralSanis Health Inc2010-10-21Not applicableCanada
Risperidonetablet.25 mg/1oralCardinal Health1993-12-29Not applicableUs
Risperidonetablet2.0 mgoralMeliapharm Inc2009-02-262014-06-25Canada
Risperidonetablet4.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Risperidonetablet3 mg/1oralJanssen Pharmaceutical, Inc.1993-12-29Not applicableUs
Risperidonetablet0.25 mgoralMeliapharm Inc2009-02-262014-06-25Canada
Risperidonetablet0.5 mgoralSanis Health Inc2010-10-21Not applicableCanada
Risperidonetablet3.0 mgoralMeliapharm Inc2009-02-262014-06-25Canada
Risperidonetablet1.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Risperidonetablet.5 mg/1oralJanssen Pharmaceutical, Inc.1993-12-29Not applicableUs
Risperidonetablet4 mgoralSanis Health Inc2010-10-21Not applicableCanada
Risperidonetablet.5 mg/1oralCardinal Health1993-12-29Not applicableUs
Risperidonetablet.5 mg/1oralREMEDYREPACK INC.2013-05-06Not applicableUs
Risperidonetablet4 mg/1oralJanssen Pharmaceutical, Inc.1993-12-29Not applicableUs
Risperidone - 0.25tablet0.25 mgoralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone - 0.5tablet0.50 mgoralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone - 1tablet1.0 mgoralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone - 2tablet2.0 mgoralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone - 3tablet3.0 mgoralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone - 4tablet4.0 mgoralPro Doc Limitee2007-10-292008-07-25Canada
Risperidone M-tabtablet, orally disintegrating3 mg/1oralJanssen Pharmaceutical, Inc.2003-04-02Not applicableUs
Risperidone M-tabtablet, orally disintegrating.5 mg/1oralJanssen Pharmaceutical, Inc.2003-04-02Not applicableUs
Risperidone M-tabtablet, orally disintegrating4 mg/1oralJanssen Pharmaceutical, Inc.2003-04-02Not applicableUs
Risperidone M-tabtablet, orally disintegrating1 mg/1oralJanssen Pharmaceutical, Inc.2003-04-02Not applicableUs
Risperidone M-tabtablet, orally disintegrating2 mg/1oralJanssen Pharmaceutical, Inc.2003-04-02Not applicableUs
Risperidone Tabletstablet3.0 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Risperidone Tabletstablet0.25 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Risperidone Tabletstablet4.0 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Risperidone Tabletstablet0.5 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Risperidone Tabletstablet1.0 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Risperidone Tabletstablet2.0 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Riva-risperidonetablet0.25 mgoralLaboratoire Riva Inc2006-07-31Not applicableCanada
Riva-risperidonetablet3.0 mgoralLaboratoire Riva Inc2006-07-31Not applicableCanada
Riva-risperidonetablet0.50 mgoralLaboratoire Riva Inc2006-07-31Not applicableCanada
Riva-risperidonetablet4.0 mgoralLaboratoire Riva Inc2006-07-31Not applicableCanada
Riva-risperidonetablet1.0 mgoralLaboratoire Riva Inc2006-07-31Not applicableCanada
Riva-risperidonetablet2.0 mgoralLaboratoire Riva Inc2006-07-31Not applicableCanada
Sandoz Risperidonetablet0.25 mgoralSandoz Canada Incorporated2006-07-052008-08-07Canada
Sandoz Risperidonetablet1.0 mgoralSandoz Canada Incorporated2006-07-05Not applicableCanada
Sandoz Risperidonetablet2.0 mgoralSandoz Canada Incorporated2006-07-05Not applicableCanada
Sandoz Risperidonetablet0.25 mgoralSandoz Canada Incorporated2007-12-21Not applicableCanada
Sandoz Risperidonetablet3.0 mgoralSandoz Canada Incorporated2006-07-05Not applicableCanada
Sandoz Risperidonetablet0.5 mgoralSandoz Canada Incorporated2006-07-052008-08-07Canada
Sandoz Risperidonetablet0.5 mgoralSandoz Canada Incorporated2007-12-21Not applicableCanada
Sandoz Risperidonetablet0.25 mgoralSandoz Canada Incorporated2007-03-082008-08-07Canada
Sandoz Risperidonetablet4.0 mgoralSandoz Canada Incorporated2006-07-05Not applicableCanada
Teva-risperidonetablet3.0 mgoralTeva Canada Limited2006-07-05Not applicableCanada
Teva-risperidonetablet4.0 mgoralTeva Canada Limited2006-07-05Not applicableCanada
Teva-risperidonetablet0.5 mgoralTeva Canada Limited2006-07-05Not applicableCanada
Teva-risperidonetablet1.0 mgoralTeva Canada Limited2006-07-05Not applicableCanada
Teva-risperidonetablet0.25 mgoralTeva Canada Limited2006-07-05Not applicableCanada
Teva-risperidonetablet2.0 mgoralTeva Canada Limited2006-07-05Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-risperidonetablet2.0 mgoralApotex Inc2006-07-05Not applicableCanada
Apo-risperidonetablet0.25 mgoralApotex Inc2006-07-05Not applicableCanada
Apo-risperidonetablet3.0 mgoralApotex Inc2006-07-05Not applicableCanada
Apo-risperidonetablet0.50 mgoralApotex Inc2006-07-05Not applicableCanada
Apo-risperidonetablet4.0 mgoralApotex Inc2006-07-05Not applicableCanada
Apo-risperidonetablet1.0 mgoralApotex Inc2006-07-05Not applicableCanada
Apo-risperidonesolution1 mgoralApotex Inc2006-07-05Not applicableCanada
Risperidonetablet, film coated4 mg/1oralClinical Solutions Wholesale, Llc2008-11-13Not applicableUs
Risperidonetablet1 mg/1oralHikma Pharmaceutical2009-06-01Not applicableUs
Risperidonetablet4 mg/1oralREMEDYREPACK INC.2015-04-14Not applicableUs
Risperidonetablet, orally disintegrating.25 mg/1oralMylan Pharmaceuticals Inc.2013-03-11Not applicableUs
Risperidonetablet, orally disintegrating4 mg/1oralRanbaxy Pharmaceuticals Inc.2010-08-06Not applicableUs
Risperidonetablet, film coated2 mg/1oralWOCKHARDT USA LLC2008-10-09Not applicableUs
Risperidonetablet, film coated2 mg/1oralCadila Healthcare Limited2008-11-13Not applicableUs
Risperidonetablet, film coated4 mg/1oralContract Pharmacy Services Pa2010-12-06Not applicableUs
Risperidonetablet, film coated1 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-11-13Not applicableUs
Risperidonetablet3 mg/1oralAjanta Pharma Limited2015-09-09Not applicableUs
Risperidonetablet4 mg/1oralSolco Healthcare US, LLC2015-06-01Not applicableUs
Risperidonetablet, film coated1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-07Not applicableUs
Risperidonetablet, film coated2 mg/1oralCardinal Health2010-11-122016-04-05Us
Risperidonetablet, film coated3 mg/1oralREMEDYREPACK INC.2013-05-01Not applicableUs
Risperidonetablet, film coated.25 mg/1oralAurolife Pharma LLC2009-10-25Not applicableUs
Risperidonetablet, orally disintegrating3 mg/1oralMylan Institutional Inc.2011-06-10Not applicableUs
Risperidonetablet, film coated2 mg/1oralCobalt Laboratories2008-12-05Not applicableUs
Risperidonetablet, film coated.5 mg/1oralREMEDYREPACK INC.2013-03-05Not applicableUs
Risperidonetablet1 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Risperidonetablet, film coated.5 mg/1oralDr. Reddy's Laboratories Limited2009-10-24Not applicableUs
Risperidonetablet, film coated4 mg/1oralCardinal Health2008-10-24Not applicableUs
Risperidonetablet, film coated4 mg/1oralWockhardt Limited2008-10-09Not applicableUs
Risperidonetablet, film coated.5 mg/1oralCardinal Health2010-11-122016-04-05Us
Risperidonetablet4 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
Risperidonetablet, coated.5 mg/1oralRatiopharm Inc2010-06-08Not applicableUs
Risperidonetablet, orally disintegrating4 mg/1oralJubilant Cadista Pharmaceuticals Inc.2010-12-01Not applicableUs
Risperidonesolution1 mg/mLoralRoxane Laboratories, Inc2009-07-29Not applicableUs
Risperidonetablet, film coated.25 mg/1oralProficient Rx LP2008-12-29Not applicableUs
Risperidonetablet, film coated3 mg/1oralbryant ranch prepack2008-12-29Not applicableUs
Risperidonesolution1 mg/mLoralAmneal Pharmaceuticals of New York, LLC2011-05-31Not applicableUs
Risperidonetablet, film coated4 mg/1oralAurobindo Pharma Limited2008-10-08Not applicableUs
Risperidonetablet, film coated.5 mg/1oralAmerican Health Packaging2008-12-02Not applicableUs
Risperidonetablet2 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Risperidonetablet, film coated.5 mg/1oralMc Kesson Contract Packaging2011-10-13Not applicableUs
Risperidonetablet, film coated2 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-09-17Not applicableUs
Risperidonetablet, film coated1 mg/1oralQualitest Pharmaceuticals2008-12-29Not applicableUs
Risperidonetablet.5 mg/1oralApotex Corp2008-09-22Not applicableUs
Risperidonetablet, film coated1 mg/1oralREMEDYREPACK INC.2013-04-24Not applicableUs
Risperidonetablet, orally disintegrating4 mg/1oralSandoz Inc2009-12-22Not applicableUs
Risperidonetablet, film coated1 mg/1oralAv Pak2014-08-27Not applicableUs
Risperidonetablet1 mg/1oralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs
Risperidonetablet.25 mg/1oralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
Risperidonetablet, film coated4 mg/1oralGen Source Rx2009-10-252016-03-29Us
Risperidonetablet, film coated3 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Risperidonetablet, orally disintegrating3 mg/1oralDr. Reddy's Laboratories Limited2009-11-30Not applicableUs
Risperidonetablet, film coated1 mg/1oralMc Kesson Contract Packaging2011-09-22Not applicableUs
Risperidonetablet3 mg/1oralREMEDYREPACK INC.2011-05-05Not applicableUs
Risperidonetablet, orally disintegrating.5 mg/1oralSandoz Inc2009-12-22Not applicableUs
Risperidonetablet, orally disintegrating2 mg/1oralPar Pharmaceutical Companies, Inc.2009-06-01Not applicableUs
Risperidonetablet, film coated3 mg/1oralAurolife Pharma LLC2009-10-25Not applicableUs
Risperidonetablet, film coated2 mg/1oralMylan Institutional Inc.2008-10-06Not applicableUs
Risperidonesolution1 mg/mLoralAtlantic Biologicals Corps2011-05-31Not applicableUs
Risperidonetablet, film coated.5 mg/1oralGen Source Rx2009-10-252016-03-29Us
Risperidonetablet, film coated2 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Risperidonetablet, film coated4 mg/1oralDr. Reddy's Laboratories Limited2009-10-24Not applicableUs
Risperidonetablet, film coated.25 mg/1oralCardinal Health2008-11-13Not applicableUs
Risperidonetablet.5 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
Risperidonetablet, film coated2 mg/1oralClinical Solutions Wholesale2008-12-29Not applicableUs
Risperidonetablet, orally disintegrating.5 mg/1oralJubilant Cadista Pharmaceuticals Inc.2010-12-01Not applicableUs
Risperidonetablet, orally disintegrating4 mg/1oralSun Pharmaceutical Industries Limited2013-04-13Not applicableUs
Risperidonetablet, orally disintegrating3 mg/1oralMylan Pharmaceuticals Inc.2011-05-11Not applicableUs
Risperidonetablet, film coated.25 mg/1oralbryant ranch prepack2008-12-29Not applicableUs
Risperidonetablet, film coated.5 mg/1oralTYA Pharmaceuticals2008-11-13Not applicableUs
Risperidonetablet, film coated.5 mg/1oralAurobindo Pharma Limited2008-10-08Not applicableUs
Risperidonetablet2 mg/1oralContract Pharmacy Services Pa2010-08-25Not applicableUs
Risperidonetablet, orally disintegrating.5 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-06-29Not applicableUs
Risperidonetablet2 mg/1oralMsm Repackaging2015-09-09Not applicableUs
Risperidonetablet, film coated4 mg/1oralAmerican Health Packaging2008-12-02Not applicableUs
Risperidonetablet.25 mg/1oralAjanta Pharma Limited2015-09-09Not applicableUs
Risperidonetablet1 mg/1oralSolco Healthcare US, LLC2015-06-01Not applicableUs
Risperidonesolution1 mg/mLoralQualitest Pharmaceuticals2010-12-03Not applicableUs
Risperidonetablet4 mg/1oralApotex Corp2008-09-22Not applicableUs
Risperidonetablet, film coated.5 mg/1oralREMEDYREPACK INC.2013-04-23Not applicableUs
Risperidonetablet2 mg/1oralMajor Pharmaceuticals2013-11-30Not applicableUs
Risperidonetablet1 mg/1oralUnit Dose Services2009-01-01Not applicableUs
Risperidonetablet, film coated.25 mg/1oralCobalt Laboratories2008-12-05Not applicableUs
Risperidonetablet3 mg/1oralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
Risperidonetablet4 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Risperidonetablet.25 mg/1oralPhysicians Total Care, Inc2010-11-15Not applicableUs
Risperidonetablet, film coated1 mg/1oralCardinal Health2008-10-24Not applicableUs
Risperidonetablet, film coated1 mg/1oralWockhardt Limited2008-10-09Not applicableUs
Risperidonetablet, film coated1 mg/1oralClinical Solutions Wholesale, Llc2008-11-13Not applicableUs
Risperidonetablet, coated4 mg/1oralRatiopharm Inc2010-06-08Not applicableUs
Risperidonetablet.5 mg/1oralREMEDYREPACK INC.2015-03-17Not applicableUs
Risperidonetablet, film coated2 mg/1oralMylan Pharmaceuticals Inc.2008-09-15Not applicableUs
Risperidonetablet, film coated.25 mg/1oralProficient Rx LP2008-11-13Not applicableUs
Risperidonetablet, film coated.25 mg/1oralWOCKHARDT USA LLC2008-10-09Not applicableUs
Risperidonetablet, film coated.25 mg/1oralCadila Healthcare Limited2008-11-13Not applicableUs
Risperidonetablet, film coated1 mg/1oralContract Pharmacy Services Pa2010-12-06Not applicableUs
Risperidonetablet, film coated.25 mg/1oralCardinal Health2008-10-24Not applicableUs
Risperidonesolution1 mg/mLoralWockhardt Limited2009-10-14Not applicableUs
Risperidonetablet, film coated.25 mg/1oralClinical Solutions Wholesale2008-12-29Not applicableUs
Risperidonetablet2 mg/1oralHikma Pharmaceutical2009-06-01Not applicableUs
Risperidonetablet1 mg/1oralREMEDYREPACK INC.2015-12-30Not applicableUs
Risperidonetablet, orally disintegrating.5 mg/1oralMylan Pharmaceuticals Inc.2011-05-11Not applicableUs
Risperidonetablet, orally disintegrating.5 mg/1oralRanbaxy Pharmaceuticals Inc.2010-08-06Not applicableUs
Risperidonetablet, film coated3 mg/1oralWOCKHARDT USA LLC2008-10-09Not applicableUs
Risperidonetablet, film coated3 mg/1oralCadila Healthcare Limited2008-11-13Not applicableUs
Risperidonetablet.25 mg/1oralContract Pharmacy Services Pa2010-08-25Not applicableUs
Risperidonetablet, film coated2 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-11-13Not applicableUs
Risperidonetablet4 mg/1oralAjanta Pharma Limited2015-09-09Not applicableUs
Risperidonetablet3 mg/1oralREMEDYREPACK INC.2010-11-08Not applicableUs
Risperidonetablet, film coated4 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-07Not applicableUs
Risperidonetablet, film coated3 mg/1oralCardinal Health2010-11-122016-04-05Us
Risperidonetablet, orally disintegrating.25 mg/1oralPar Pharmaceutical Companies, Inc.2009-06-01Not applicableUs
Risperidonetablet, film coated.5 mg/1oralAurolife Pharma LLC2009-10-25Not applicableUs
Risperidonetablet, film coated.25 mg/1oralMylan Institutional Inc.2008-10-06Not applicableUs
Risperidonetablet, film coated3 mg/1oralCobalt Laboratories2008-12-05Not applicableUs
Risperidonetablet, film coated.5 mg/1oralREMEDYREPACK INC.2013-03-182016-04-05Us
Risperidonetablet2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Risperidonetablet, film coated1 mg/1oralDr. Reddy's Laboratories Limited2009-10-24Not applicableUs
Risperidonesolution1 mg/mLoralSilarx Pharmaceuticals, Inc2015-01-30Not applicableUs
Risperidonetablet, orally disintegrating4 mg/1oralDr. Reddy's Laboratories Limited2009-11-30Not applicableUs
Risperidonetablet.25 mg/1oralCardinal Health2013-11-30Not applicableUs
Risperidonetablet1 mg/1oralClinical Solutions Wholesale, Llc2009-01-01Not applicableUs
Risperidonetablet, coated1 mg/1oralRatiopharm Inc2010-06-08Not applicableUs
Risperidonesolution1 mg/mLoralApotex Corp.2009-07-29Not applicableUs
Risperidonetablet, film coated.25 mg/1oralMylan Pharmaceuticals Inc.2008-09-15Not applicableUs
Risperidonetablet, film coated.5 mg/1oralProficient Rx LP2008-12-29Not applicableUs
Risperidonetablet, film coated4 mg/1oralbryant ranch prepack2008-12-29Not applicableUs
Risperidonetablet, orally disintegrating.5 mg/1oralCadila Healthcare Limited2010-06-29Not applicableUs
Risperidonesolution1 mg/mLoralAurobindo Pharma Limited2009-09-15Not applicableUs
Risperidonetablet, film coated1 mg/1oralAmerican Health Packaging2008-12-02Not applicableUs
Risperidonetablet3 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Risperidonetablet, film coated4 mg/1oralMc Kesson Contract Packaging2013-05-13Not applicableUs
Risperidonetablet, film coated3 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-09-17Not applicableUs
Risperidonetablet, film coated2 mg/1oralQualitest Pharmaceuticals2008-12-29Not applicableUs
Risperidonetablet1 mg/1oralApotex Corp2008-09-22Not applicableUs
Risperidonetablet, film coated3 mg/1oralREMEDYREPACK INC.2013-04-23Not applicableUs
Risperidonetablet.25 mg/1oralMajor Pharmaceuticals2013-11-30Not applicableUs
Risperidonetablet, film coated2 mg/1oralAv Pak2014-08-27Not applicableUs
Risperidonetablet2 mg/1oralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs
Risperidonetablet.5 mg/1oralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
Risperidonetablet.5 mg/1oralH.J. Harkins Company, Inc.2009-01-01Not applicableUs
Risperidonetablet3 mg/1oralContract Pharmacy Services Pa2010-08-25Not applicableUs
Risperidonetablet, orally disintegrating1 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-06-29Not applicableUs
Risperidonetablet1 mg/1oralPd Rx Pharmaceuticals, Inc.2009-01-01Not applicableUs
Risperidonetablet, film coated2 mg/1oralMc Kesson Contract Packaging2011-09-14Not applicableUs
Risperidonetablet1 mg/1oralREMEDYREPACK INC.2013-04-30Not applicableUs
Risperidonetablet, orally disintegrating1 mg/1oralSandoz Inc2009-12-22Not applicableUs
Risperidonetablet, orally disintegrating3 mg/1oralPar Pharmaceutical Companies, Inc.2009-06-01Not applicableUs
Risperidonetablet, film coated4 mg/1oralAurolife Pharma LLC2009-10-25Not applicableUs
Risperidonetablet, film coated3 mg/1oralMylan Institutional Inc.2008-10-06Not applicableUs
Risperidonetablet.25 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Risperidonetablet, film coated1 mg/1oralGen Source Rx2009-10-252016-03-29Us
Risperidonetablet, film coated2 mg/1oralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Risperidonetablet, orally disintegrating.5 mg/1oralDr. Reddy's Laboratories Limited2009-02-24Not applicableUs
Risperidonetablet, film coated.5 mg/1oralCardinal Health2008-11-13Not applicableUs
Risperidonetablet1 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
Risperidonetablet, film coated4 mg/1oralClinical Solutions Wholesale2008-12-29Not applicableUs
Risperidonetablet, orally disintegrating1 mg/1oralJubilant Cadista Pharmaceuticals Inc.2010-12-01Not applicableUs
Risperidonetablet, orally disintegrating.5 mg/1oralSun Pharmaceutical Industries Limited2013-04-13Not applicableUs
Risperidonetablet, orally disintegrating4 mg/1oralMylan Pharmaceuticals Inc.2011-05-11Not applicableUs
Risperidonetablet, film coated1 mg/1oralbryant ranch prepack2008-12-29Not applicableUs
Risperidonetablet, film coated1 mg/1oralTYA Pharmaceuticals2008-11-13Not applicableUs
Risperidonetablet, film coated1 mg/1oralAurobindo Pharma Limited2008-10-08Not applicableUs
Risperidonetablet, film coated.5 mg/1oralCadila Healthcare Limited2008-11-13Not applicableUs
Risperidonetablet, film coated2 mg/1oralContract Pharmacy Services Pa2010-12-06Not applicableUs
Risperidonetablet, film coated.25 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-11-13Not applicableUs
Risperidonetablet.5 mg/1oralAjanta Pharma Limited2015-09-09Not applicableUs
Risperidonetablet2 mg/1oralSolco Healthcare US, LLC2015-06-01Not applicableUs
Risperidonetablet, film coated.25 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-07Not applicableUs
Risperidonetablet, film coated1 mg/1oralCardinal Health2012-09-19Not applicableUs
Risperidonetablet, film coated.25 mg/1oralREMEDYREPACK INC.2013-05-01Not applicableUs
Risperidonetablet3 mg/1oralMajor Pharmaceuticals2013-11-30Not applicableUs
Risperidonetablet, orally disintegrating1 mg/1oralMylan Institutional Inc.2011-06-10Not applicableUs
Risperidonetablet, film coated.5 mg/1oralCobalt Laboratories2008-12-05Not applicableUs
Risperidonetablet4 mg/1oralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
Risperidonetablet, film coated2 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Risperidonetablet2 mg/1oralPhysicians Total Care, Inc2011-04-08Not applicableUs
Risperidonetablet, film coated2 mg/1oralCardinal Health2008-10-24Not applicableUs
Risperidonetablet, film coated2 mg/1oralWockhardt Limited2008-10-09Not applicableUs
Risperidonetablet, film coated2 mg/1oralClinical Solutions Wholesale, Llc2008-11-13Not applicableUs
Risperidonetablet.25 mg/1oralHikma Pharmaceutical2009-06-01Not applicableUs
Risperidonetablet2 mg/1oralREMEDYREPACK INC.2015-03-27Not applicableUs
Risperidonetablet, film coated3 mg/1oralMylan Pharmaceuticals Inc.2008-09-15Not applicableUs
Risperidonetablet2 mg/1oralProficient Rx LP2014-04-23Not applicableUs
Risperidonetablet, film coated.5 mg/1oralWOCKHARDT USA LLC2008-10-09Not applicableUs
Risperidonetablet3 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Risperidonetablet, film coated2 mg/1oralDr. Reddy's Laboratories Limited2009-10-24Not applicableUs
Risperidonetablet, film coated1 mg/1oralCardinal Health2008-12-02Not applicableUs
Risperidonetablet, film coated2 mg/1oralLake Erie Medical DBA Quality Care Products LLC2013-06-18Not applicableUs
Risperidonetablet, film coated.5 mg/1oralClinical Solutions Wholesale2008-12-29Not applicableUs
Risperidonetablet3 mg/1oralHikma Pharmaceutical2009-06-01Not applicableUs
Risperidonetablet, film coated1 mg/1oralDIRECT RX2014-01-01Not applicableUs
Risperidonetablet, orally disintegrating1 mg/1oralMylan Pharmaceuticals Inc.2011-05-11Not applicableUs
Risperidonetablet, orally disintegrating1 mg/1oralRanbaxy Pharmaceuticals Inc.2010-08-06Not applicableUs
Risperidonetablet, film coated4 mg/1oralWOCKHARDT USA LLC2008-10-09Not applicableUs
Risperidonetablet, film coated4 mg/1oralCadila Healthcare Limited2008-11-13Not applicableUs
Risperidonetablet.5 mg/1oralContract Pharmacy Services Pa2010-08-25Not applicableUs
Risperidonetablet, film coated3 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-11-13Not applicableUs
Risperidonesolution1 mg/mLoralTris Pharma Inc2012-12-12Not applicableUs
Risperidonetablet.5 mg/1oralREMEDYREPACK INC.2011-04-11Not applicableUs
Risperidonetablet, film coated2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-07Not applicableUs
Risperidonetablet, orally disintegrating.5 mg/1oralPar Pharmaceutical Companies, Inc.2009-06-01Not applicableUs
Risperidonetablet, film coated1 mg/1oralAurolife Pharma LLC2009-10-25Not applicableUs
Risperidonetablet, film coated.5 mg/1oralMylan Institutional Inc.2008-10-06Not applicableUs
Risperidonetablet, film coated4 mg/1oralCobalt Laboratories2008-12-05Not applicableUs
Risperidonetablet, film coated1 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs
Risperidonetablet1 mg/1oralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
Risperidonetablet2 mg/1oralH.J. Harkins Company, Inc.2009-01-01Not applicableUs
Risperidonetablet1 mg/1oralPhysicians Total Care, Inc2008-07-23Not applicableUs
Risperidonesolution1 mg/mLoralDr. Reddy's Laboratories Limited2009-07-29Not applicableUs
Risperidonetablet, film coated.25 mg/1oralWockhardt Limited2008-10-09Not applicableUs
Risperidonetablet2 mg/1oralClinical Solutions Wholesale, Llc2009-01-01Not applicableUs
Risperidonetablet, coated2 mg/1oralRatiopharm Inc2010-06-08Not applicableUs
Risperidonetablet3 mg/1oralREMEDYREPACK INC.2015-03-03Not applicableUs
Risperidonetablet, film coated.5 mg/1oralMylan Pharmaceuticals Inc.2008-09-15Not applicableUs
Risperidonetablet, film coated2 mg/1oralProficient Rx LP2008-12-29Not applicableUs
Risperidonetablet, film coated1 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-02-13Not applicableUs
Risperidonetablet, orally disintegrating1 mg/1oralCadila Healthcare Limited2010-06-29Not applicableUs
Risperidonetablet, film coated.25 mg/1oralContract Pharmacy Services Pa2010-12-06Not applicableUs
Risperidonetablet, film coated2 mg/1oralAmerican Health Packaging2008-12-02Not applicableUs
Risperidonesolution1 mg/mLoralHeritage Pharmaceuticals Inc.2013-07-15Not applicableUs
Risperidonetablet2 mg/1oralREMEDYREPACK INC.2015-12-23Not applicableUs
Risperidonetablet.25 mg/1oralSolco Healthcare US, LLC2015-06-01Not applicableUs
Risperidonetablet, film coated4 mg/1oralQualitest Pharmaceuticals2008-12-29Not applicableUs
Risperidonetablet2 mg/1oralApotex Corp2008-09-22Not applicableUs
Risperidonetablet, film coated4 mg/1oralREMEDYREPACK INC.2013-05-01Not applicableUs
Risperidonetablet.5 mg/1oralMajor Pharmaceuticals2013-11-30Not applicableUs
Risperidonetablet, film coated3 mg/1oralAv Pak2014-08-27Not applicableUs
Risperidonetablet3 mg/1oralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs
Risperidonetablet2 mg/1oralTYA Pharmaceuticals2012-04-25Not applicableUs
Risperidonetablet, film coated2 mg/1oralAurobindo Pharma Limited2008-10-08Not applicableUs
Risperidonetablet4 mg/1oralContract Pharmacy Services Pa2010-08-25Not applicableUs
Risperidonetablet, orally disintegrating2 mg/1oralZydus Pharmaceuticals (USA) Inc.2010-06-29Not applicableUs
Risperidonetablet, film coated4 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-09-17Not applicableUs
Risperidonetablet, film coated3 mg/1oralMc Kesson Contract Packaging2012-01-03Not applicableUs
Risperidonetablet.25 mg/1oralREMEDYREPACK INC.2011-03-28Not applicableUs
Risperidonetablet, orally disintegrating2 mg/1oralSandoz Inc2009-12-22Not applicableUs
Risperidonetablet, orally disintegrating4 mg/1oralPar Pharmaceutical Companies, Inc.2009-06-01Not applicableUs
Risperidonetablet.25 mg/1oralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs
Risperidonetablet, film coated4 mg/1oralMylan Institutional Inc.2008-10-06Not applicableUs
Risperidonetablet.5 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Risperidonetablet, film coated2 mg/1oralGen Source Rx2009-10-252016-03-29Us
Risperidonetablet, film coated4 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Risperidonetablet, orally disintegrating1 mg/1oralDr. Reddy's Laboratories Limited2009-10-06Not applicableUs
Risperidonetablet, film coated1 mg/1oralCardinal Health2008-11-13Not applicableUs
Risperidonetablet2 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
Risperidonetablet, film coated3 mg/1oralClinical Solutions Wholesale2008-12-29Not applicableUs
Risperidonetablet, orally disintegrating2 mg/1oralJubilant Cadista Pharmaceuticals Inc.2010-12-01Not applicableUs
Risperidonetablet, orally disintegrating1 mg/1oralSun Pharmaceutical Industries Limited2013-04-13Not applicableUs
Risperidonetablet, film coated.25 mg/1oralQualitest Pharmaceuticals2008-12-29Not applicableUs
Risperidonetablet, film coated2 mg/1oralbryant ranch prepack2008-12-29Not applicableUs
Risperidonetablet, orally disintegrating3 mg/1oralRanbaxy Pharmaceuticals Inc.2010-08-06Not applicableUs
Risperidonetablet, film coated1 mg/1oralWOCKHARDT USA LLC2008-10-09Not applicableUs
Risperidonetablet, film coated1 mg/1oralCadila Healthcare Limited2008-11-13Not applicableUs
Risperidonetablet, film coated3 mg/1oralContract Pharmacy Services Pa2010-12-06Not applicableUs
Risperidonetablet, film coated.5 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-11-13Not applicableUs
Risperidonetablet2 mg/1oralAjanta Pharma Limited2015-09-09Not applicableUs
Risperidonetablet3 mg/1oralSolco Healthcare US, LLC2015-06-01Not applicableUs
Risperidonetablet, film coated.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-07Not applicableUs
Risperidonetablet, film coated1 mg/1oralCardinal Health2010-11-122016-04-05Us
Risperidonetablet, film coated2 mg/1oralREMEDYREPACK INC.2013-05-01Not applicableUs
Risperidonetablet4 mg/1oralMajor Pharmaceuticals2013-11-30Not applicableUs
Risperidonetablet, orally disintegrating2 mg/1oralMylan Institutional Inc.2011-06-10Not applicableUs
Risperidonetablet, film coated1 mg/1oralCobalt Laboratories2008-12-05Not applicableUs
Risperidonesolution1 mg/mLoralBreckenridge Pharmaceutical, Inc.2014-01-29Not applicableUs
Risperidonetablet, film coated1 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Risperidonetablet, film coated.25 mg/1oralDr. Reddy's Laboratories Limited2009-10-24Not applicableUs
Risperidonetablet, film coated3 mg/1oralCardinal Health2008-10-24Not applicableUs
Risperidonetablet, film coated3 mg/1oralWockhardt Limited2008-10-09Not applicableUs
Risperidonetablet, film coated3 mg/1oralClinical Solutions Wholesale, Llc2008-11-13Not applicableUs
Risperidonetablet.5 mg/1oralHikma Pharmaceutical2009-06-01Not applicableUs
Risperidonetablet.25 mg/1oralREMEDYREPACK INC.2015-04-14Not applicableUs
Risperidonetablet, film coated4 mg/1oralMylan Pharmaceuticals Inc.2008-09-15Not applicableUs
Risperidonetablet, film coated1 mg/1oralMylan Institutional Inc.2008-10-06Not applicableUs
Risperidonetablet2 mg/1oralSTAT Rx USA LLC2009-01-01Not applicableUs
Risperidonetablet, film coated.25 mg/1oralGen Source Rx2009-10-252016-03-29Us
Risperidonetablet, film coated.5 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Risperidonetablet, film coated3 mg/1oralDr. Reddy's Laboratories Limited2009-10-24Not applicableUs
Risperidonetablet1 mg/1oralCardinal Health2013-11-30Not applicableUs
Risperidonetablet.25 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
Risperidonetablet, film coated1 mg/1oralClinical Solutions Wholesale2008-12-29Not applicableUs
Risperidonetablet4 mg/1oralHikma Pharmaceutical2009-06-01Not applicableUs
Risperidonetablet, orally disintegrating3 mg/1oralSun Pharmaceutical Industries Limited2013-04-13Not applicableUs
Risperidonetablet, orally disintegrating2 mg/1oralMylan Pharmaceuticals Inc.2011-05-11Not applicableUs
Risperidonetablet, orally disintegrating2 mg/1oralRanbaxy Pharmaceuticals Inc.2010-08-06Not applicableUs
Risperidonesolution1 mg/mLoralWockhardt USA LLC.2009-10-14Not applicableUs
Risperidonetablet, film coated.25 mg/1oralAurobindo Pharma Limited2008-10-08Not applicableUs
Risperidonetablet1 mg/1oralContract Pharmacy Services Pa2010-08-25Not applicableUs
Risperidonetablet, film coated4 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-11-13Not applicableUs
Risperidonetablet1 mg/1oralAidarex Pharmaceuticals LLC2009-01-01Not applicableUs
Risperidonetablet.5 mg/1oralProficient Rx LP2015-09-09Not applicableUs
Risperidonetablet.25 mg/1oralREMEDYREPACK INC.2013-04-24Not applicableUs
Risperidonetablet, film coated3 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-04-07Not applicableUs
Risperidonetablet, orally disintegrating1 mg/1oralPar Pharmaceutical Companies, Inc.2009-10-26Not applicableUs
Risperidonetablet, film coated2 mg/1oralAurolife Pharma LLC2009-10-25Not applicableUs
Risperidonetablet3 mg/1oralApotex Corp2008-09-22Not applicableUs
Risperidonetablet, film coated4 mg/1oralREMEDYREPACK INC.2013-04-23Not applicableUs
Risperidonetablet1 mg/1oralMajor Pharmaceuticals2013-11-30Not applicableUs
Risperidonetablet, film coated4 mg/1oralAv Pak2014-08-27Not applicableUs
Risperidonetablet4 mg/1oralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs
Risperidonetablet2 mg/1oralBreckenridge Pharmaceutical, Inc.2012-04-25Not applicableUs
Risperidonetablet, film coated2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Risperidonetablet.5 mg/1oralPhysicians Total Care, Inc2009-10-28Not applicableUs
Risperidonetablet, film coated.5 mg/1oralCardinal Health2008-10-24Not applicableUs
Risperidonetablet, film coated.5 mg/1oralWockhardt Limited2008-10-09Not applicableUs
Risperidonetablet3 mg/1oralClinical Solutions Wholesale, Llc2009-01-01Not applicableUs
Risperidonetablet, coated3 mg/1oralRatiopharm Inc2010-06-08Not applicableUs
Risperidonetablet1 mg/1oralREMEDYREPACK INC.2015-03-12Not applicableUs
Risperidonetablet, film coated1 mg/1oralMylan Pharmaceuticals Inc.2008-09-15Not applicableUs
Risperidonetablet1 mg/1oralProficient Rx LP2014-04-23Not applicableUs
Risperidonetablet, film coated2 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-03-19Not applicableUs
Risperidonetablet, orally disintegrating2 mg/1oralCadila Healthcare Limited2010-06-29Not applicableUs
Risperidonetablet, film coated.5 mg/1oralContract Pharmacy Services Pa2010-12-06Not applicableUs
Risperidonetablet, film coated3 mg/1oralAmerican Health Packaging2008-12-02Not applicableUs
Risperidonetablet1 mg/1oralAjanta Pharma Limited2015-09-09Not applicableUs
Risperidonetablet.5 mg/1oralSolco Healthcare US, LLC2015-06-01Not applicableUs
Risperidonetablet, film coated3 mg/1oralQualitest Pharmaceuticals2008-12-29Not applicableUs
Risperidonetablet, orally disintegrating2 mg/1oralSun Pharmaceutical Industries Limited2013-04-13Not applicableUs
Risperidonetablet, film coated.5 mg/1oralQualitest Pharmaceuticals2008-12-29Not applicableUs
Risperidonetablet, film coated.5 mg/1oralbryant ranch prepack2008-12-29Not applicableUs
Risperidonetablet4 mg/1oralTYA Pharmaceuticals2012-04-25Not applicableUs
Risperidonetablet, film coated3 mg/1oralAurobindo Pharma Limited2008-10-08Not applicableUs
Risperidonetablet, film coated.25 mg/1oralAmerican Health Packaging2008-12-02Not applicableUs
Risperidonetablet, film coated.25 mg/1oralMc Kesson Contract Packaging2011-10-13Not applicableUs
Risperidonetablet, film coated1 mg/1oralAphena Pharma Solutions Tennessee, Llc2008-09-17Not applicableUs
Risperidonetablet.25 mg/1oralApotex Corp2008-09-22Not applicableUs
Risperidonetablet, film coated2 mg/1oralREMEDYREPACK INC.2013-05-01Not applicableUs
Risperidonetablet, orally disintegrating3 mg/1oralSandoz Inc2009-12-22Not applicableUs
Risperidonetablet, film coated.5 mg/1oralAv Pak2014-08-27Not applicableUs
Risperidonetablet.5 mg/1oralTorrent Pharmaceuticals Limited2009-01-01Not applicableUs
Risperidonesolution1 mg/mLoralTaro Pharmaceuticals U.S.A., Inc.2011-02-07Not applicableUs
Risperidonetablet1 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Risperidonetablet, film coated3 mg/1oralGen Source Rx2009-10-252016-03-29Us
Risperidonetablet3 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Risperidonetablet, orally disintegrating2 mg/1oralDr. Reddy's Laboratories Limited2009-02-24Not applicableUs
Risperidonetablet, film coated.25 mg/1oralCardinal Health2010-11-122016-04-05Us
Risperidonetablet3 mg/1oralCaraco Pharmaceutical Laboratories, Ltd.2014-03-10Not applicableUs
Risperidonetablet, coated.25 mg/1oralRatiopharm Inc2010-06-08Not applicableUs
Risperidonetablet, orally disintegrating3 mg/1oralJubilant Cadista Pharmaceuticals Inc.2010-12-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Risperidal M-TabJanssen
RisperinNot Available
RispoleptNot Available
RispolinNot Available
SequinanNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIL6UH7ZF8HC
CAS number106266-06-2
WeightAverage: 410.4845
Monoisotopic: 410.211804333
Chemical FormulaC23H27FN4O2
InChI KeyInChIKey=RAPZEAPATHNIPO-UHFFFAOYSA-N
InChI
InChI=1S/C23H27FN4O2/c1-15-18(23(29)28-10-3-2-4-21(28)25-15)9-13-27-11-7-16(8-12-27)22-19-6-5-17(24)14-20(19)30-26-22/h5-6,14,16H,2-4,7-13H2,1H3
IUPAC Name
3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4H,6H,7H,8H,9H-pyrido[1,2-a]pyrimidin-4-one
SMILES
CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as pyridopyrimidines. These are compounds containing a pyridopyrimidine, which consists of a pyridine fused to a pyrimidine. Pyridine is 6-membered ring consisting of five carbon atoms and a nitrogen atom. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridopyrimidines
Sub ClassNot Available
Direct ParentPyridopyrimidines
Alternative Parents
Substituents
  • Pyridopyrimidine
  • Benzisoxazole
  • Aralkylamine
  • Pyrimidone
  • Fluorobenzene
  • Benzenoid
  • Pyrimidine
  • Pyridine
  • Piperidine
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Oxazole
  • Isoxazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactam
  • Oxacycle
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of schizophrenia in adults and in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17. May also be used to manage symptoms of inappropriate behavior due to aggression and/or psychosis in patients with severe dementia.
PharmacodynamicsRisperidone is an atypical antipsychotic medication. It is most often used to treat delusional psychosis (including schizophrenia), but risperidone is also used to treat some forms of bipolar disorder and psychotic depression. It also has shown some success in treating symptoms of Asperger's Syndrome and autism. Risperidone is now the most commonly prescribed antipsychotic medication in the United States.
Mechanism of actionBlockade of dopaminergic D2 receptors in the limbic system alleviates positive symptoms of schizophrenia such as hallucinations, delusions, and erratic behavior and speech. Blockade of serotonergic 5-HT2 receptors in the mesocortical tract, causes an excess of dopamine and an increase in dopamine transmission, resulting in an increase in dopamine transmission and an elimination of core negative symptoms. Dopamine receptors in the nigrostriatal pathway are not affected by risperidone and extrapyramidal effects are avoided. Like other 5-HT2 antagonists, risperidone also binds at alpha(1)-adrenergic receptors and, to a lesser extent, at histamine H1 and alpha(2)-adrenergic receptors.
Related Articles
AbsorptionWell absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.
Volume of distribution
  • 1 to 2 L/kg
Protein bindingRisperidone, ~88% bound; 9-hydroxyrisperidone, ~77% bound.
Metabolism

Extensively metabolized by hepatic cytochrome P450 2D6 isozyme to 9-hydroxyrisperidone, which has approximately the same receptor binding affinity as risperidone. Hydroxylation is dependent on debrisoquine 4-hydroxylase and metabolism is sensitive to genetic polymorphisms in debrisoquine 4-hydroxylase. Risperidone also undergoes N-dealkylation to a lesser extent.

SubstrateEnzymesProduct
Risperidone
9-hydroxyrisperidoneDetails
Route of eliminationRisperidone is extensively metabolized in the liver.In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects.
Half life20-24 hours
ClearanceNot Available
ToxicitySymptoms of overdose include drowsiness, sedation, tachycardia, hypotension, and extrapyramidal symptoms. LD50=82.1mg/kg (orally in mice).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9925
Caco-2 permeable-0.5057
P-glycoprotein substrateSubstrate0.6163
P-glycoprotein inhibitor IInhibitor0.8564
P-glycoprotein inhibitor IIInhibitor0.9361
Renal organic cation transporterInhibitor0.6491
CYP450 2C9 substrateNon-substrate0.8235
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.82
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8459
Ames testNon AMES toxic0.5302
CarcinogenicityNon-carcinogens0.8204
BiodegradationNot ready biodegradable0.99
Rat acute toxicity3.8290 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.65
hERG inhibition (predictor II)Inhibitor0.8062
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
  • Ortho mcneil janssen pharmaceutical inc
  • Apotex inc richmond hill
  • Aurobindo pharma ltd
  • Dr reddys laboratories ltd
  • Precision dose inc
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Wockhardt ltd
  • Par pharmaceutical inc
  • Ranbaxy laboratories inc
  • Sandoz inc
  • Zydus pharmaceuticals usa inc
  • Actavis totowa llc
  • Apotex inc
  • Cadista pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Pliva hrvatska doo
  • Ratiopharm
  • Synthon pharmaceuticals inc
  • Torrent pharmaceuticals ltd
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • West ward pharmaceuticals corp
Packagers
Dosage forms
FormRouteStrength
Tabletoral0.50 mg
Tabletoral1.0 mg
Tabletoral2.0 mg
Tabletoral3.0 mg
Tabletoral4.0 mg
Tabletoral0.25 mg
Tabletoral0.5 mg
Tabletoral1 mg
Tabletoral2 mg
Tabletoral3 mg
Tabletoral4 mg
Tabletoral5 mg
Kit
Powder for suspension, sustained-release; kitintramuscular12.5 mg
Powder for suspension, sustained-release; kitintramuscular25 mg
Powder for suspension, sustained-release; kitintramuscular37.5 mg
Powder for suspension, sustained-release; kitintramuscular50 mg
Tablet (orally disintegrating)oral0.5 mg
Tablet (orally disintegrating)oral1 mg
Tablet (orally disintegrating)oral2 mg
Tablet (orally disintegrating)oral3 mg
Tablet (orally disintegrating)oral4 mg
Solutionoral1 mg
Solutionoral1 mg/mL
Tabletoral.25 mg/1
Tabletoral.5 mg/1
Tabletoral1 mg/1
Tabletoral2 mg/1
Tabletoral3 mg/1
Tabletoral4 mg/1
Tablet, coatedoral.25 mg/1
Tablet, coatedoral.5 mg/1
Tablet, coatedoral1 mg/1
Tablet, coatedoral2 mg/1
Tablet, coatedoral3 mg/1
Tablet, coatedoral4 mg/1
Tablet, film coatedoral.25 mg/1
Tablet, film coatedoral.5 mg/1
Tablet, film coatedoral1 mg/1
Tablet, film coatedoral2 mg/1
Tablet, film coatedoral3 mg/1
Tablet, film coatedoral4 mg/1
Tablet, orally disintegratingoral.25 mg/1
Tablet, orally disintegratingoral.5 mg/1
Tablet, orally disintegratingoral1 mg/1
Tablet, orally disintegratingoral2 mg/1
Tablet, orally disintegratingoral3 mg/1
Tablet, orally disintegratingoral4 mg/1
Prices
Unit descriptionCostUnit
Risperdal consta 50 mg syr592.93USD syringe
Risperdal consta 37.5 mg syr444.68USD syringe
Risperdal consta 25 mg syr296.46USD syringe
Risperdal 1 mg/ml Solution 30ml Bottle204.42USD bottle
Risperdal M-TAB 28 1 mg Dispersible Tablet Box196.08USD box
Risperdal M-TAB 28 0.5 mg Dispersible Tablet Bottle167.82USD bottle
Risperidone 1 mg/ml Solution 30ml Bottle158.66USD bottle
Risperdal consta 12.5 mg syr148.22USD syringe
Risperdal m-tab 4 mg odt18.55USD tablet
Risperdal 4 mg tablet16.47USD tablet
Risperidone m-tab 4 mg odt15.16USD tablet
Risperdal m-tab 3 mg odt13.81USD tablet
Risperdal 3 mg tablet11.45USD tablet
Risperidone m-tab 3 mg odt11.29USD tablet
Risperdal m-tab 2 mg odt10.95USD tablet
Risperidone 4 mg tablet9.0USD tablet
Risperidone m-tab 2 mg odt8.95USD tablet
Risperdal 2 mg tablet6.94USD tablet
Risperdal m-tab 1 mg odt6.73USD tablet
Risperidone 3 mg tablet6.63USD tablet
Risperdal 1 mg tablet6.12USD tablet
Risperdal m-tab 0.5 mg odt5.76USD tablet
Risperidone 2 mg tablet5.59USD tablet
Risperidone m-tab 1 mg odt5.5USD tablet
Risperidone M-TAB 0.5 mg Dispersible Tablet4.9USD dispersible tablet
Risperidone m-tab 0.5 mg odt4.71USD tablet
Risperdal M-Tab 4 mg Disintegrating Tablet4.6USD tablet
Risperdal 0.25 mg tablet4.56USD tablet
Risperidone 0.25 mg odt4.48USD tablet
Risperdal 0.5 mg tablet3.62USD tablet
Risperdal M-Tab 3 mg Disintegrating Tablet3.44USD tablet
Risperidone 1 mg tablet3.27USD tablet
Risperidone 0.5 mg tablet3.03USD tablet
Apo-Risperidone 4 mg Tablet2.53USD tablet
Co Risperidone 4 mg Tablet2.53USD tablet
Mylan-Risperidone 4 mg Tablet2.53USD tablet
Novo-Risperidone 4 mg Tablet2.53USD tablet
Phl-Risperidone 4 mg Tablet2.53USD tablet
Pms-Risperidone 4 mg Tablet2.53USD tablet
Ran-Risperidone 4 mg Tablet2.53USD tablet
Ratio-Risperidone 4 mg Tablet2.53USD tablet
Rbx-Risperidone 4 mg Tablet2.53USD tablet
Sandoz Risperidone 4 mg Tablet2.53USD tablet
Risperdal M-Tab 2 mg Disintegrating Tablet2.29USD tablet
Apo-Risperidone 3 mg Tablet1.9USD tablet
Co Risperidone 3 mg Tablet1.9USD tablet
Mylan-Risperidone 3 mg Tablet1.9USD tablet
Novo-Risperidone 3 mg Tablet1.9USD tablet
Phl-Risperidone 3 mg Tablet1.9USD tablet
Pms-Risperidone 3 mg Tablet1.9USD tablet
Ran-Risperidone 3 mg Tablet1.9USD tablet
Ratio-Risperidone 3 mg Tablet1.9USD tablet
Rbx-Risperidone 3 mg Tablet1.9USD tablet
Sandoz Risperidone 3 mg Tablet1.9USD tablet
Risperidone 0.25 mg tablet1.88USD tablet
Apo-Risperidone 2 mg Tablet1.26USD tablet
Co Risperidone 2 mg Tablet1.26USD tablet
Mylan-Risperidone 2 mg Tablet1.26USD tablet
Novo-Risperidone 2 mg Tablet1.26USD tablet
Phl-Risperidone 2 mg Tablet1.26USD tablet
Pms-Risperidone 2 mg Tablet1.26USD tablet
Ran-Risperidone 2 mg Tablet1.26USD tablet
Ratio-Risperidone 2 mg Tablet1.26USD tablet
Rbx-Risperidone 2 mg Tablet1.26USD tablet
Sandoz Risperidone 2 mg Tablet1.26USD tablet
Risperdal M-Tab 1 mg Disintegrating Tablet1.16USD tablet
Risperdal M-Tab 0.5 mg Disintegrating Tablet0.84USD tablet
Apo-Risperidone 1 mg Tablet0.63USD tablet
Co Risperidone 1 mg Tablet0.63USD tablet
Mylan-Risperidone 1 mg Tablet0.63USD tablet
Novo-Risperidone 1 mg Tablet0.63USD tablet
Phl-Risperidone 1 mg Tablet0.63USD tablet
Pms-Risperidone 1 mg Tablet0.63USD tablet
Ran-Risperidone 1 mg Tablet0.63USD tablet
Ratio-Risperidone 1 mg Tablet0.63USD tablet
Rbx-Risperidone 1 mg Tablet0.63USD tablet
Sandoz Risperidone 1 mg Tablet0.63USD tablet
Apo-Risperidone 0.5 mg Tablet0.46USD tablet
Co Risperidone 0.5 mg Tablet0.46USD tablet
Mylan-Risperidone 0.5 mg Tablet0.46USD tablet
Novo-Risperidone 0.5 mg Tablet0.46USD tablet
Phl-Risperidone 0.5 mg Tablet0.46USD tablet
Pms-Risperidone 0.5 mg Tablet0.46USD tablet
Ran-Risperidone 0.5 mg Tablet0.46USD tablet
Ratio-Risperidone 0.5 mg Tablet0.46USD tablet
Rbx-Risperidone 0.5 mg Tablet0.46USD tablet
Sandoz Risperidone 0.5 mg Tablet0.46USD tablet
Apo-Risperidone 0.25 mg Tablet0.27USD tablet
Co Risperidone 0.25 mg Tablet0.27USD tablet
Mylan-Risperidone 0.25 mg Tablet0.27USD tablet
Novo-Risperidone 0.25 mg Tablet0.27USD tablet
Phl-Risperidone 0.25 mg Tablet0.27USD tablet
Pms-Risperidone 0.25 mg Tablet0.27USD tablet
Ran-Risperidone 0.25 mg Tablet0.27USD tablet
Ratio-Risperidone 0.25 mg Tablet0.27USD tablet
Rbx-Risperidone 0.25 mg Tablet0.27USD tablet
Sandoz Risperidone 0.25 mg Tablet0.27USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2194564 No1998-01-272015-07-04Canada
CA2406536 No2009-12-222021-04-19Canada
US5792477 Yes1997-11-022017-11-02Us
US5916598 Yes1997-11-022017-11-02Us
US6110921 No1993-11-192013-11-19Us
US6194006 Yes1999-06-302019-06-30Us
US6224905 Yes1997-12-102017-12-10Us
US6379703 Yes1999-06-302019-06-30Us
US6403114 Yes1997-11-022017-11-02Us
US6596316 Yes1999-06-302019-06-30Us
US6667061 Yes2000-11-252020-11-25Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point170 °CPhysProp
water solubility2.8mg/LNot Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.171 mg/mLALOGPS
logP3.27ALOGPS
logP2.63ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)8.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area61.94 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity114.55 m3·mol-1ChemAxon
Polarizability45.27 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

DrugSyn.org

US4804663
General References
  1. Altschuler EL, Kast RE: The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses. 2005;65(3):585-6. [PubMed:16004936 ]
  2. Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009 Jan;29(1):64-73. doi: 10.1592/phco.29.1.64. [PubMed:19113797 ]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  4. Kemp DE, Canan F, Goldstein BI, McIntyre RS: Long-acting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther. 2009 Jun;26(6):588-99. doi: 10.1007/s12325-009-0039-0. Epub 2009 Jun 26. [PubMed:19562274 ]
  5. Szarfman A, Tonning JM, Levine JG, Doraiswamy PM: Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy. 2006 Jun;26(6):748-58. [PubMed:16716128 ]
  6. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  7. Yamanouchi Y, Iwata N, Suzuki T, Kitajima T, Ikeda M, Ozaki N: Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 2003;3(6):356-61. [PubMed:14610521 ]
External Links
ATC CodesN05AX08
AHFS Codes
  • 28:16.08.04
PDB EntriesNot Available
FDA labelDownload (2.54 MB)
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineRisperidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineRisperidone may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Risperidone is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Risperidone can be decreased when combined with Abiraterone.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Risperidone.
AcebutololAcebutolol may increase the hypotensive activities of Risperidone.
AcebutololRisperidone may increase the atrioventricular blocking (AV block) activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Aceprometazine.
AcetaminophenThe serum concentration of Risperidone can be increased when it is combined with Acetaminophen.
AcetazolamideAcetazolamide may increase the hypotensive activities of Risperidone.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Risperidone.
adipiplonThe risk or severity of adverse effects can be increased when Risperidone is combined with adipiplon.
AfatinibThe serum concentration of Risperidone can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Risperidone is combined with Agomelatine.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Risperidone.
AlbendazoleThe serum concentration of Risperidone can be increased when it is combined with Albendazole.
AldesleukinAldesleukin may increase the hypotensive activities of Risperidone.
AldosteroneThe serum concentration of Risperidone can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Risperidone can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Alfaxalone.
AlfentanilThe serum concentration of Risperidone can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Risperidone is combined with Alfentanil.
AliskirenAliskiren may increase the hypotensive activities of Risperidone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Risperidone.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Risperidone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Risperidone is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Risperidone.
AlprenololRisperidone may increase the atrioventricular blocking (AV block) activities of Alprenolol.
AmantadineThe serum concentration of Risperidone can be increased when it is combined with Amantadine.
AmilorideAmiloride may increase the hypotensive activities of Risperidone.
AmineptineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Amineptine.
Aminohippuric acidThe serum concentration of Risperidone can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Risperidone can be decreased when it is combined with Amiodarone.
AmiodaroneRisperidone may increase the QTc-prolonging activities of Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Risperidone is combined with Amisulpride.
AmitriptylineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Risperidone is combined with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Risperidone.
AmobarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Amobarbital.
AmoxapineThe metabolism of Risperidone can be decreased when combined with Amoxapine.
AmoxapineThe risk or severity of adverse effects can be increased when Risperidone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Risperidone is combined with Amperozide.
AmphetamineRisperidone may decrease the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Risperidone can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Risperidone can be increased when it is combined with Amsacrine.
Amyl NitriteAmyl Nitrite may increase the hypotensive activities of Risperidone.
AnagrelideRisperidone may increase the QTc-prolonging activities of Anagrelide.
ApraclonidineApraclonidine may increase the hypotensive activities of Risperidone.
AprepitantThe serum concentration of Risperidone can be increased when it is combined with Aprepitant.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Risperidone.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Risperidone.
ArotinololRisperidone may increase the atrioventricular blocking (AV block) activities of Arotinolol.
Arsenic trioxideRisperidone may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherRisperidone may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Risperidone can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Risperidone is combined with Asenapine.
AstemizoleThe serum concentration of Risperidone can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Risperidone can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Risperidone.
AtenololRisperidone may increase the atrioventricular blocking (AV block) activities of Atenolol.
AtomoxetineThe metabolism of Risperidone can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Risperidone can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Azaperone.
AzelastineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Risperidone can be increased when it is combined with Azelastine.
Azilsartan medoxomilAzilsartan medoxomil may increase the hypotensive activities of Risperidone.
AzithromycinRisperidone may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Risperidone can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Risperidone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Barbital.
BedaquilineRisperidone may increase the QTc-prolonging activities of Bedaquiline.
BefunololRisperidone may increase the atrioventricular blocking (AV block) activities of Befunolol.
BenazeprilBenazepril may increase the hypotensive activities of Risperidone.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Risperidone.
BenzocaineThe serum concentration of Risperidone can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Benzocaine.
BenzphetamineRisperidone may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Risperidone is combined with Benzyl alcohol.
BepridilThe serum concentration of Risperidone can be increased when it is combined with Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Risperidone.
BetaxololRisperidone may increase the atrioventricular blocking (AV block) activities of Betaxolol.
BevantololRisperidone may increase the atrioventricular blocking (AV block) activities of Bevantolol.
BexaroteneThe serum concentration of Risperidone can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Risperidone can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the hypotensive activities of Risperidone.
BisoprololRisperidone may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
BoceprevirThe metabolism of Risperidone can be decreased when combined with Boceprevir.
BopindololRisperidone may increase the atrioventricular blocking (AV block) activities of Bopindolol.
BortezomibThe metabolism of Risperidone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Risperidone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Risperidone can be increased when it is combined with Bosutinib.
BretyliumBretylium may increase the hypotensive activities of Risperidone.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Risperidone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
BrimonidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Risperidone.
BrompheniramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Brotizolam.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Risperidone.
BufuralolRisperidone may increase the atrioventricular blocking (AV block) activities of Bufuralol.
BumetanideBumetanide may increase the hypotensive activities of Risperidone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Risperidone.
BupranololRisperidone may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BuprenorphineThe serum concentration of Risperidone can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Buprenorphine.
BupropionThe metabolism of Risperidone can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Risperidone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Risperidone.
ButacaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Risperidone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Risperidone is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Risperidone.
CabazitaxelThe serum concentration of Risperidone can be increased when it is combined with Cabazitaxel.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Risperidone.
CaffeineThe serum concentration of Risperidone can be increased when it is combined with Caffeine.
CanagliflozinCanagliflozin may increase the hypotensive activities of Risperidone.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Risperidone.
CandesartanCandesartan may increase the hypotensive activities of Risperidone.
CaptoprilCaptopril may increase the hypotensive activities of Risperidone.
CarbamazepineThe serum concentration of Risperidone can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Risperidone is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Risperidone is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Risperidone is combined with Carisoprodol.
CarteololCarteolol may increase the hypotensive activities of Risperidone.
CarteololRisperidone may increase the atrioventricular blocking (AV block) activities of Carteolol.
CarvedilolCarvedilol may increase the hypotensive activities of Risperidone.
CarvedilolRisperidone may increase the atrioventricular blocking (AV block) activities of Carvedilol.
CaspofunginThe serum concentration of Risperidone can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Risperidone.
CelecoxibThe metabolism of Risperidone can be decreased when combined with Celecoxib.
CeliprololRisperidone may increase the atrioventricular blocking (AV block) activities of Celiprolol.
CeritinibThe serum concentration of Risperidone can be increased when it is combined with Ceritinib.
CeritinibRisperidone may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Risperidone is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Risperidone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Chloroprocaine.
ChloroquineRisperidone may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe serum concentration of Risperidone can be increased when it is combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Risperidone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorphenamine.
ChlorphentermineRisperidone may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineRisperidone may increase the QTc-prolonging activities of Chlorpromazine.
ChlorpromazineThe serum concentration of Risperidone can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Risperidone.
ChlorpropamideThe serum concentration of Risperidone can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Risperidone can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorprothixene.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Risperidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Risperidone can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Risperidone can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Risperidone can be decreased when it is combined with Cholic Acid.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Risperidone.
CilazaprilCilazapril may increase the hypotensive activities of Risperidone.
CimetidineThe serum concentration of Risperidone can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Risperidone can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Risperidone.
CiprofloxacinRisperidone may increase the QTc-prolonging activities of Ciprofloxacin.
CiprofloxacinThe serum concentration of Risperidone can be increased when it is combined with Ciprofloxacin.
CisaprideRisperidone may increase the QTc-prolonging activities of Cisapride.
CitalopramThe metabolism of Risperidone can be decreased when combined with Citalopram.
CitalopramThe risk or severity of adverse effects can be increased when Risperidone is combined with Citalopram.
ClarithromycinRisperidone may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe serum concentration of Risperidone can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Risperidone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Risperidone is combined with Clemastine.
ClevidipineClevidipine may increase the hypotensive activities of Risperidone.
ClidiniumThe risk or severity of adverse effects can be increased when Risperidone is combined with Clidinium.
ClobazamThe metabolism of Risperidone can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Risperidone is combined with Clobazam.
ClofazimineThe serum concentration of Risperidone can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when Risperidone is combined with clomethiazole.
ClomipramineThe metabolism of Risperidone can be decreased when combined with Clomipramine.
ClomipramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Clonazepam.
ClonidineClonidine may increase the hypotensive activities of Risperidone.
ClonidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Risperidone.
ClotrimazoleThe metabolism of Risperidone can be decreased when combined with Clotrimazole.
ClozapineRisperidone may increase the QTc-prolonging activities of Clozapine.
ClozapineThe metabolism of Risperidone can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Risperidone can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Risperidone.
ColchicineThe serum concentration of Risperidone can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Risperidone can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Risperidone can be increased when it is combined with Conivaptan.
CrizotinibRisperidone may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Risperidone can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyclizine.
CyclobenzaprineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Cyclobenzaprine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyclobenzaprine.
CyclophosphamideThe serum concentration of Risperidone can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Risperidone can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Cyproheptadine.
DabrafenibThe serum concentration of Risperidone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Risperidone can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Risperidone can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dantrolene.
DapagliflozinDapagliflozin may increase the hypotensive activities of Risperidone.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Risperidone.
DapoxetineThe metabolism of Risperidone can be decreased when combined with Dapoxetine.
DapoxetineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dapoxetine.
DarifenacinThe metabolism of Risperidone can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Risperidone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Risperidone can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Risperidone can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Risperidone can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Risperidone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Risperidone is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Risperidone is combined with Desflurane.
DesipramineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Desipramine.
DesloratadineThe serum concentration of Risperidone can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Risperidone.
DetomidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Detomidine.
DexamethasoneThe serum concentration of Risperidone can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dexbrompheniramine.
DexmedetomidineDexmedetomidine may increase the hypotensive activities of Risperidone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dexmedetomidine.
DextroamphetamineRisperidone may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Risperidone.
DextromoramideThe risk or severity of adverse effects can be increased when Risperidone is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Risperidone.
DezocineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Diazepam.
DiclofenacThe serum concentration of Risperidone can be increased when it is combined with Diclofenac.
DiclofenamideDiclofenamide may increase the hypotensive activities of Risperidone.
DifenoxinThe risk or severity of adverse effects can be increased when Risperidone is combined with Difenoxin.
DigoxinThe serum concentration of Risperidone can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydrocodeine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Risperidone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Dihydromorphine.
DiltiazemDiltiazem may increase the hypotensive activities of Risperidone.
DimenhydrinateThe risk or severity of adverse effects can be increased when Risperidone is combined with Dimenhydrinate.
DinutuximabDinutuximab may increase the hypotensive activities of Risperidone.
DiphenhydramineThe metabolism of Risperidone can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Risperidone is combined with Diphenoxylate.
DipyridamoleDipyridamole may increase the hypotensive activities of Risperidone.
DisopyramideRisperidone may increase the QTc-prolonging activities of Disopyramide.
DofetilideRisperidone may increase the QTc-prolonging activities of Dofetilide.
DolasetronRisperidone may increase the QTc-prolonging activities of Dolasetron.
DomperidoneRisperidone may increase the QTc-prolonging activities of Domperidone.
DoramectinThe risk or severity of adverse effects can be increased when Risperidone is combined with Doramectin.
DosulepinThe therapeutic efficacy of Risperidone can be decreased when used in combination with Dosulepin.
DoxazosinDoxazosin may increase the hypotensive activities of Risperidone.
DoxepinThe therapeutic efficacy of Risperidone can be decreased when used in combination with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Risperidone is combined with Doxepin.
DoxorubicinThe serum concentration of Risperidone can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Risperidone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
DoxylamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Risperidone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
DronedaroneThe metabolism of Risperidone can be decreased when combined with Dronedarone.
DronedaroneRisperidone may increase the QTc-prolonging activities of Dronedarone.
DroperidolRisperidone may increase the QTc-prolonging activities of Droperidol.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Risperidone.
DrotebanolThe risk or severity of adverse effects can be increased when Risperidone is combined with Drotebanol.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Risperidone.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Risperidone.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Risperidone.
EcgonineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Risperidone is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Risperidone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Risperidone is combined with Efavirenz.
ElbasvirThe serum concentration of Risperidone can be increased when it is combined with Elbasvir.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Risperidone.
EliglustatRisperidone may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Risperidone can be decreased when combined with Eliglustat.
EmpagliflozinEmpagliflozin may increase the hypotensive activities of Risperidone.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Risperidone.
EnalaprilEnalapril may increase the hypotensive activities of Risperidone.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Risperidone.
EntacaponeThe risk or severity of adverse effects can be increased when Risperidone is combined with Entacapone.
EnzalutamideThe serum concentration of Risperidone can be increased when it is combined with Enzalutamide.
EplerenoneEplerenone may increase the hypotensive activities of Risperidone.
EprosartanEprosartan may increase the hypotensive activities of Risperidone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Risperidone.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Risperidone.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Risperidone.
ErythromycinRisperidone may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Risperidone can be decreased when combined with Erythromycin.
EscitalopramThe metabolism of Risperidone can be decreased when combined with Escitalopram.
EscitalopramThe risk or severity of adverse effects can be increased when Risperidone is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Risperidone can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Esmirtazapine.
EsmololEsmolol may increase the hypotensive activities of Risperidone.
EsmololRisperidone may increase the atrioventricular blocking (AV block) activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Estazolam.
EstramustineThe serum concentration of Risperidone can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Risperidone can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Risperidone can be decreased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Risperidone.
Etacrynic acidEtacrynic acid may increase the hypotensive activities of Risperidone.
EthanolRisperidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Risperidone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Risperidone.
EthosuximideThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Risperidone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Risperidone.
EtoperidoneThe metabolism of Risperidone can be decreased when combined with Etoperidone.
EtoperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Etoperidone.
EtoposideThe serum concentration of Risperidone can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Etorphine.
EtravirineThe serum concentration of Risperidone can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Risperidone.
EzogabineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Risperidone is combined with Felbamate.
FelodipineFelodipine may increase the hypotensive activities of Risperidone.
FencamfamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Fencamfamine.
FenfluramineThe metabolism of Risperidone can be decreased when combined with Fenfluramine.
FenfluramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Risperidone.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Risperidone.
FexofenadineThe serum concentration of Risperidone can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Fexofenadine.
FidaxomicinThe serum concentration of Risperidone can be increased when it is combined with Fidaxomicin.
FlecainideRisperidone may increase the QTc-prolonging activities of Flecainide.
FlibanserinThe risk or severity of adverse effects can be increased when Risperidone is combined with Flibanserin.
FluconazoleThe metabolism of Risperidone can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Flunitrazepam.
FluoxetineThe metabolism of Risperidone can be decreased when combined with Fluoxetine.
FluoxetineThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluoxetine.
FlupentixolThe serum concentration of Risperidone can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Risperidone is combined with Flupentixol.
FluphenazineThe serum concentration of Risperidone can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluphenazine.
FlurazepamThe serum concentration of Risperidone can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluticasone Propionate.
FluvoxamineThe metabolism of Risperidone can be decreased when combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Fluvoxamine.
FosamprenavirThe metabolism of Risperidone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Risperidone can be increased when it is combined with Fosaprepitant.
FosinoprilFosinopril may increase the hypotensive activities of Risperidone.
FosphenytoinThe risk or severity of adverse effects can be increased when Risperidone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Risperidone is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Risperidone.
FurosemideFurosemide may increase the hypotensive activities of Risperidone.
Fusidic AcidThe serum concentration of Risperidone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Risperidone is combined with gabapentin enacarbil.
Gadobenic acidRisperidone may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Risperidone is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Risperidone can be increased when it is combined with Gefitinib.
GemifloxacinRisperidone may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Risperidone can be increased when it is combined with Genistein.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Risperidone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Risperidone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Risperidone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Risperidone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Risperidone.
GlutethimideThe risk or severity of adverse effects can be increased when Risperidone is combined with Glutethimide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Risperidone.
GlyburideThe serum concentration of Risperidone can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Risperidone can be increased when it is combined with Glycerol.
GoserelinRisperidone may increase the QTc-prolonging activities of Goserelin.
Gramicidin DThe serum concentration of Risperidone can be increased when it is combined with Gramicidin D.
GranisetronRisperidone may increase the QTc-prolonging activities of Granisetron.
GrepafloxacinThe serum concentration of Risperidone can be increased when it is combined with Grepafloxacin.
GuanfacineGuanfacine may increase the hypotensive activities of Risperidone.
GuanfacineThe risk or severity of adverse effects can be increased when Risperidone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Halazepam.
HaloperidolRisperidone may increase the QTc-prolonging activities of Haloperidol.
HaloperidolThe serum concentration of Risperidone can be increased when it is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Risperidone is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Risperidone is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Hexobarbital.
HydralazineHydralazine may increase the hypotensive activities of Risperidone.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Risperidone.
HydrocodoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Risperidone can be increased when it is combined with Hydrocortisone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Risperidone.
Hydroxyamphetamine hydrobromideRisperidone may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
HydroxyzineThe risk or severity of adverse effects can be increased when Risperidone is combined with Hydroxyzine.
IbutilideRisperidone may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Risperidone can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Iloperidone.
ImatinibThe metabolism of Risperidone can be decreased when combined with Imatinib.
ImipramineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Imipramine.
IndalpineThe metabolism of Risperidone can be decreased when combined with Indalpine.
IndalpineThe risk or severity of adverse effects can be increased when Risperidone is combined with Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Risperidone.
IndenololRisperidone may increase the atrioventricular blocking (AV block) activities of Indenolol.
IndinavirThe serum concentration of Risperidone can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Risperidone can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Risperidone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Risperidone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Risperidone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Risperidone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Risperidone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Risperidone.
IrbesartanIrbesartan may increase the hypotensive activities of Risperidone.
IsavuconazoniumThe metabolism of Risperidone can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Risperidone.
IsofluraneThe risk or severity of adverse effects can be increased when Risperidone is combined with Isoflurane.
IsoniazidThe metabolism of Risperidone can be decreased when combined with Isoniazid.
Isosorbide DinitrateIsosorbide Dinitrate may increase the hypotensive activities of Risperidone.
Isosorbide MononitrateIsosorbide Mononitrate may increase the hypotensive activities of Risperidone.
IsoxsuprineIsoxsuprine may increase the hypotensive activities of Risperidone.
IsradipineIsradipine may increase the hypotensive activities of Risperidone.
ItraconazoleThe serum concentration of Risperidone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Risperidone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Risperidone can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Risperidone can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketobemidone.
KetoconazoleThe serum concentration of Risperidone can be increased when it is combined with Ketoconazole.
LabetalolLabetalol may increase the hypotensive activities of Risperidone.
LabetalolRisperidone may increase the atrioventricular blocking (AV block) activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Risperidone is combined with Lamotrigine.
LansoprazoleThe serum concentration of Risperidone can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Risperidone can be increased when it is combined with Lapatinib.
LenvatinibRisperidone may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideRisperidone may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamThe risk or severity of adverse effects can be increased when Risperidone is combined with Levetiracetam.
LevobunololLevobunolol may increase the hypotensive activities of Risperidone.
LevobupivacaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Risperidone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Risperidone is combined with Levodopa.
LevofloxacinRisperidone may increase the QTc-prolonging activities of Levofloxacin.
LevofloxacinThe serum concentration of Risperidone can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Risperidone is combined with Levomethadyl Acetate.
LevomilnacipranThe metabolism of Risperidone can be decreased when combined with Levomilnacipran.
LevomilnacipranThe risk or severity of adverse effects can be increased when Risperidone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Risperidone is combined with Levorphanol.
LevothyroxineThe serum concentration of Risperidone can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Risperidone can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Risperidone.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Risperidone.
LiothyronineThe serum concentration of Risperidone can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Risperidone can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Risperidone.
LisdexamfetamineRisperidone may decrease the stimulatory activities of Lisdexamfetamine.
LisinoprilLisinopril may increase the hypotensive activities of Risperidone.
LithiumLithium may increase the neurotoxic activities of Risperidone.
LithiumThe risk or severity of adverse effects can be increased when Risperidone is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Risperidone is combined with Lofentanil.
LomitapideThe serum concentration of Risperidone can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Risperidone can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Risperidone can be increased when it is combined with Lopinavir.
LopinavirRisperidone may increase the QTc-prolonging activities of Lopinavir.
LoratadineThe serum concentration of Risperidone can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Risperidone.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Risperidone.
LosartanLosartan may increase the hypotensive activities of Risperidone.
LovastatinThe metabolism of Risperidone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Risperidone.
Lu AA21004The metabolism of Risperidone can be decreased when combined with Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Risperidone is combined with Lu AA21004.
LuliconazoleThe serum concentration of Risperidone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Risperidone can be decreased when it is combined with Lumacaftor.
LumefantrineRisperidone may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Risperidone can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Risperidone is combined with Magnesium Sulfate.
MannitolMannitol may increase the hypotensive activities of Risperidone.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Risperidone.
MebendazoleThe serum concentration of Risperidone can be increased when it is combined with Mebendazole.
MecamylamineMecamylamine may increase the hypotensive activities of Risperidone.
MeclizineThe risk or severity of adverse effects can be increased when Risperidone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Medetomidine.
MefloquineThe serum concentration of Risperidone can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Risperidone can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Risperidone is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Melperone.
MephentermineRisperidone may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Mepivacaine.
MeprobamateThe serum concentration of Risperidone can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Risperidone is combined with Meprobamate.
MequitazineRisperidone may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Metaxalone.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Risperidone.
MethadoneRisperidone may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Risperidone is combined with Methadyl Acetate.
MethamphetamineRisperidone may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methaqualone.
MethazolamideMethazolamide may increase the hypotensive activities of Risperidone.
MethocarbamolThe risk or severity of adverse effects can be increased when Risperidone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Risperidone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Risperidone is combined with Methsuximide.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Risperidone.
MethyldopaMethyldopa may increase the hypotensive activities of Risperidone.
MethylphenidateThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Methylphenobarbital.
MetipranololMetipranolol may increase the hypotensive activities of Risperidone.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Risperidone.
MetolazoneMetolazone may increase the hypotensive activities of Risperidone.
MetoprololMetoprolol may increase the hypotensive activities of Risperidone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Risperidone.
MetyrosineRisperidone may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Risperidone.
MianserinThe therapeutic efficacy of Risperidone can be decreased when used in combination with Mianserin.
MibefradilThe serum concentration of Risperidone can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Risperidone can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Risperidone can be decreased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Midazolam.
MifepristoneThe metabolism of Risperidone can be decreased when combined with Mifepristone.
MifepristoneRisperidone may increase the QTc-prolonging activities of Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Risperidone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Risperidone.
MilnacipranThe metabolism of Risperidone can be decreased when combined with Milnacipran.
MilnacipranThe risk or severity of adverse effects can be increased when Risperidone is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
MinoxidilMinoxidil may increase the hypotensive activities of Risperidone.
MirabegronThe metabolism of Risperidone can be decreased when combined with Mirabegron.
MirtazapineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Mirtazapine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Risperidone.
MitomycinThe serum concentration of Risperidone can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Risperidone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Risperidone can be decreased when it is combined with Mitoxantrone.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Risperidone.
ModafinilThe serum concentration of Risperidone can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the hypotensive activities of Risperidone.
MolindoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Molindone.
MorphineThe serum concentration of Risperidone can be increased when it is combined with Morphine.
MorphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Morphine.
MoxifloxacinRisperidone may increase the QTc-prolonging activities of Moxifloxacin.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Risperidone.
NabiloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Nabilone.
NadololNadolol may increase the hypotensive activities of Risperidone.
NadololRisperidone may increase the atrioventricular blocking (AV block) activities of Nadolol.
NafcillinThe serum concentration of Risperidone can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Risperidone is combined with Nalbuphine.
NaltrexoneThe serum concentration of Risperidone can be increased when it is combined with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Risperidone.
NaringeninThe serum concentration of Risperidone can be increased when it is combined with Naringenin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Risperidone.
NebivololNebivolol may increase the hypotensive activities of Risperidone.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Risperidone.
NelfinavirThe serum concentration of Risperidone can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Risperidone can be increased when it is combined with Neostigmine.
NesiritideNesiritide may increase the hypotensive activities of Risperidone.
NetupitantThe serum concentration of Risperidone can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Risperidone can be decreased when combined with Nevirapine.
NicardipineNicardipine may increase the hypotensive activities of Risperidone.
NifedipineNifedipine may increase the hypotensive activities of Risperidone.
NilotinibThe metabolism of Risperidone can be decreased when combined with Nilotinib.
NilotinibRisperidone may increase the QTc-prolonging activities of Nilotinib.
NimodipineNimodipine may increase the hypotensive activities of Risperidone.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Risperidone.
NisoldipineNisoldipine may increase the hypotensive activities of Risperidone.
NitrazepamThe serum concentration of Risperidone can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Nitrazepam.
NitrendipineThe serum concentration of Risperidone can be increased when it is combined with Nitrendipine.
NitroglycerinNitroglycerin may increase the hypotensive activities of Risperidone.
NitroprussideNitroprusside may increase the hypotensive activities of Risperidone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Risperidone is combined with Nitrous oxide.
NorethisteroneThe serum concentration of Risperidone can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Normethadone.
NortriptylineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Nortriptyline.
NortriptylineThe risk or severity of adverse effects can be increased when Risperidone is combined with Nortriptyline.
OfloxacinRisperidone may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe metabolism of Risperidone can be decreased when combined with Olanzapine.
OlanzapineThe risk or severity of adverse effects can be increased when Risperidone is combined with Olanzapine.
OlaparibThe metabolism of Risperidone can be decreased when combined with Olaparib.
OlmesartanOlmesartan may increase the hypotensive activities of Risperidone.
OlopatadineThe risk or severity of adverse effects can be increased when Risperidone is combined with Olopatadine.
OmeprazoleThe serum concentration of Risperidone can be increased when it is combined with Omeprazole.
OndansetronRisperidone may increase the QTc-prolonging activities of Ondansetron.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Risperidone.
OpiumThe risk or severity of adverse effects can be increased when Risperidone is combined with Opium.
OrphenadrineRisperidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Risperidone.
OsanetantThe risk or severity of adverse effects can be increased when Risperidone is combined with Osanetant.
OsimertinibThe serum concentration of Risperidone can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Risperidone.
OxymorphoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxymorphone.
P-NitrophenolThe serum concentration of Risperidone can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Risperidone can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Risperidone can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Paliperidone.
Palmitic AcidThe serum concentration of Risperidone can be increased when it is combined with Palmitic Acid.
PanobinostatRisperidone may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Risperidone can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Risperidone can be increased when it is combined with Pantoprazole.
PapaverinePapaverine may increase the hypotensive activities of Risperidone.
ParaldehydeRisperidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Risperidone.
ParoxetineThe metabolism of Risperidone can be decreased when combined with Paroxetine.
ParoxetineThe risk or severity of adverse effects can be increased when Risperidone is combined with Paroxetine.
PazopanibRisperidone may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Risperidone can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololPenbutolol may increase the hypotensive activities of Risperidone.
PenbutololRisperidone may increase the atrioventricular blocking (AV block) activities of Penbutolol.
PentamidineRisperidone may increase the QTc-prolonging activities of Pentamidine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Risperidone.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Risperidone.
PerampanelThe risk or severity of adverse effects can be increased when Risperidone is combined with Perampanel.
PerflutrenRisperidone may increase the QTc-prolonging activities of Perflutren.
PerindoprilPerindopril may increase the hypotensive activities of Risperidone.
PerospironeThe risk or severity of adverse effects can be increased when Risperidone is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Risperidone.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Risperidone.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Risperidone.
PhenobarbitalThe serum concentration of Risperidone can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Risperidone is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Risperidone is combined with Phenoxyethanol.
PhentermineRisperidone may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Risperidone is combined with Phenytoin.
PimozideThe serum concentration of Risperidone can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Risperidone is combined with Pimozide.
PindololPindolol may increase the hypotensive activities of Risperidone.
PindololRisperidone may increase the atrioventricular blocking (AV block) activities of Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Risperidone.
PipamperoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Pipotiazine.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Risperidone.
PizotifenThe risk or severity of adverse effects can be increased when Risperidone is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Risperidone can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe risk or severity of adverse effects can be increased when Risperidone is combined with Pomalidomide.
PonatinibThe serum concentration of Risperidone can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Risperidone can be increased when it is combined with Posaconazole.
PractololRisperidone may increase the atrioventricular blocking (AV block) activities of Practolol.
PramipexoleRisperidone may increase the sedative activities of Pramipexole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Risperidone.
PramocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Pramocaine.
PravastatinThe serum concentration of Risperidone can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Prazepam.
PrazosinPrazosin may increase the hypotensive activities of Risperidone.
PrednisoneThe serum concentration of Risperidone can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Risperidone.
PrilocaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Prilocaine.
PrimaquineRisperidone may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Primidone.
ProbenecidThe serum concentration of Risperidone can be increased when it is combined with Probenecid.
ProcainamideRisperidone may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Risperidone.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Risperidone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Risperidone.
ProgesteroneThe serum concentration of Risperidone can be decreased when it is combined with Progesterone.
PromazineRisperidone may increase the QTc-prolonging activities of Promazine.
PromazineThe metabolism of Risperidone can be decreased when combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Risperidone.
PropafenoneRisperidone may increase the QTc-prolonging activities of Propafenone.
PropafenoneThe serum concentration of Risperidone can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Risperidone is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Propoxycaine.
PropranololPropranolol may increase the hypotensive activities of Risperidone.
PropranololRisperidone may increase the atrioventricular blocking (AV block) activities of Propranolol.
ProtriptylineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Risperidone is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Risperidone is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Quazepam.
QuercetinThe serum concentration of Risperidone can be increased when it is combined with Quercetin.
QuetiapineQuetiapine may increase the hypotensive activities of Risperidone.
QuetiapineThe risk or severity of adverse effects can be increased when Risperidone is combined with Quetiapine.
QuinacrineThe serum concentration of Risperidone can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Risperidone.
QuinaprilQuinapril may increase the hypotensive activities of Risperidone.
QuinidineThe serum concentration of Risperidone can be increased when it is combined with Quinidine.
QuinidineRisperidone may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Risperidone can be increased when it is combined with Quinine.
QuinineRisperidone may increase the QTc-prolonging activities of Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Risperidone is combined with Ramelteon.
RamiprilRamipril may increase the hypotensive activities of Risperidone.
RanitidineThe serum concentration of Risperidone can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Risperidone can be increased when it is combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Risperidone.
ReboxetineThe serum concentration of Risperidone can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Risperidone can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Risperidone is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Risperidone.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Risperidone.
ReserpineReserpine may increase the hypotensive activities of Risperidone.
ReserpineThe risk or severity of adverse effects can be increased when Risperidone is combined with Reserpine.
RifabutinThe metabolism of Risperidone can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Risperidone can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Risperidone can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Risperidone can be increased when it is combined with Rilpivirine.
RiociguatRiociguat may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Risperidone can be decreased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Risperidone.
RolapitantThe serum concentration of Risperidone can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Romifidine.
RopiniroleRisperidone may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Risperidone can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Risperidone.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Risperidone.
RotigotineRisperidone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Risperidone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Risperidone is combined with S-Ethylisothiourea.
SaquinavirRisperidone may increase the QTc-prolonging activities of Saquinavir.
SaquinavirThe serum concentration of Risperidone can be decreased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Risperidone.
ScopolamineThe serum concentration of Risperidone can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Risperidone.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Risperidone.
SertindoleThe risk or severity of adverse effects can be increased when Risperidone is combined with Sertindole.
SertralineThe metabolism of Risperidone can be decreased when combined with Sertraline.
SertralineThe risk or severity of adverse effects can be increased when Risperidone is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Risperidone is combined with Sevoflurane.
SildenafilThe metabolism of Risperidone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Risperidone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Risperidone can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Risperidone can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Risperidone can be decreased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Risperidone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Risperidone is combined with Sodium oxybate.
SorafenibThe serum concentration of Risperidone can be increased when it is combined with Sorafenib.
SotalolSotalol may increase the hypotensive activities of Risperidone.
SotalolRisperidone may increase the atrioventricular blocking (AV block) activities of Sotalol.
SpironolactoneSpironolactone may increase the hypotensive activities of Risperidone.
St. John's WortThe serum concentration of Risperidone can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Risperidone can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Risperidone is combined with Stiripentol.
StreptozocinThe serum concentration of Risperidone can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Risperidone.
SulfinpyrazoneThe serum concentration of Risperidone can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleRisperidone may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Risperidone can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Risperidone.
SulpirideThe risk or severity of adverse effects can be increased when Risperidone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Risperidone.
SunitinibThe serum concentration of Risperidone can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Risperidone is combined with Suvorexant.
TacrineThe serum concentration of Risperidone can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Risperidone can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Risperidone can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Risperidone.
TasimelteonThe risk or severity of adverse effects can be increased when Risperidone is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Risperidone can be increased when it is combined with Taurocholic Acid.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Risperidone.
TelaprevirThe metabolism of Risperidone can be decreased when combined with Telaprevir.
TelavancinRisperidone may increase the QTc-prolonging activities of Telavancin.
TelithromycinRisperidone may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Risperidone can be decreased when combined with Telithromycin.
TelmisartanTelmisartan may increase the hypotensive activities of Risperidone.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Risperidone.
TemsirolimusThe serum concentration of Risperidone can be increased when it is combined with Temsirolimus.
TerazosinTerazosin may increase the hypotensive activities of Risperidone.
TerbinafineThe metabolism of Risperidone can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Risperidone can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Risperidone can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Risperidone can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Risperidone.
TetracaineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Risperidone is combined with Tetrodotoxin.
ThalidomideRisperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Risperidone.
ThiamylalThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Risperidone.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Risperidone.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Risperidone.
ThiothixeneThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiagabine.
TianeptineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Tianeptine.
TicagrelorThe serum concentration of Risperidone can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Risperidone can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tiletamine.
TimololTimolol may increase the hypotensive activities of Risperidone.
TimololRisperidone may increase the atrioventricular blocking (AV block) activities of Timolol.
TipranavirThe metabolism of Risperidone can be decreased when combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Risperidone.
TizanidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Tizanidine.
TocilizumabThe serum concentration of Risperidone can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Risperidone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Risperidone.
TolcaponeThe risk or severity of adverse effects can be increased when Risperidone is combined with Tolcapone.
TolvaptanThe serum concentration of Risperidone can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Risperidone is combined with Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Risperidone.
ToremifeneRisperidone may increase the QTc-prolonging activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Risperidone.
TrandolaprilTrandolapril may increase the hypotensive activities of Risperidone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Risperidone is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Risperidone.
TrazodoneThe metabolism of Risperidone can be decreased when combined with Trazodone.
TrazodoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Trazodone.
TriamtereneTriamterene may increase the hypotensive activities of Risperidone.
TriazolamThe risk or severity of adverse effects can be increased when Risperidone is combined with Triazolam.
TrifluoperazineThe serum concentration of Risperidone can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Risperidone can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Triflupromazine.
TrimethoprimThe serum concentration of Risperidone can be decreased when it is combined with Trimethoprim.
TrimipramineThe therapeutic efficacy of Risperidone can be decreased when used in combination with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Risperidone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Triprolidine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Risperidone.
TroleandomycinThe serum concentration of Risperidone can be increased when it is combined with Troleandomycin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Risperidone.
ValsartanValsartan may increase the hypotensive activities of Risperidone.
VandetanibRisperidone may increase the QTc-prolonging activities of Vandetanib.
VemurafenibRisperidone may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Risperidone.
VerapamilVerapamil may increase the hypotensive activities of Risperidone.
VigabatrinThe risk or severity of adverse effects can be increased when Risperidone is combined with Vigabatrin.
VilazodoneThe metabolism of Risperidone can be decreased when combined with Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Vilazodone.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Risperidone.
VinblastineThe serum concentration of Risperidone can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Risperidone can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Risperidone can be increased when it is combined with Vinorelbine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Risperidone.
VoriconazoleThe metabolism of Risperidone can be decreased when combined with Voriconazole.
VortioxetineThe metabolism of Risperidone can be decreased when combined with Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Risperidone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Risperidone is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Risperidone is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Risperidone is combined with Ziconotide.
ZimelidineThe metabolism of Risperidone can be decreased when combined with Zimelidine.
ZimelidineThe risk or severity of adverse effects can be increased when Risperidone is combined with Zimelidine.
ZiprasidoneThe metabolism of Risperidone can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Risperidone is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Risperidone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Risperidone.
ZonisamideThe risk or severity of adverse effects can be increased when Risperidone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Risperidone is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Risperidone is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Risperidone is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  2. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  3. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  4. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Catafau AM, Corripio I, Perez V, Martin JC, Schotte A, Carrio I, Alvarez E: Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Res. 2006 Dec 1;148(2-3):175-83. Epub 2006 Oct 23. [PubMed:17059881 ]
  2. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  3. Lane HY, Lee CC, Chang YC, Lu CT, Huang CH, Chang WH: Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function. Int J Neuropsychopharmacol. 2004 Dec;7(4):461-70. Epub 2004 May 12. [PubMed:15140279 ]
  4. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699 ]
  5. Remington G, Mamo D, Labelle A, Reiss J, Shammi C, Mannaert E, Mann S, Kapur S: A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry. 2006 Mar;163(3):396-401. [PubMed:16513859 ]
  6. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Megens AA, Awouters FH, Schotte A, Meert TF, Dugovic C, Niemegeers CJ, Leysen JE: Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl). 1994 Feb;114(1):9-23. [PubMed:7531353 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  2. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  3. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  4. Nourian Z, Mow T, Muftic D, Burek S, Pedersen ML, Matz J, Mulvany MJ: Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. Psychopharmacology (Berl). 2008 Jul;199(1):15-27. doi: 10.1007/s00213-007-1064-9. Epub 2008 Jun 10. [PubMed:18542932 ]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  6. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Eltze M: In functional experiments, risperidone is selective, not for the B, but for the A subtype of alpha 1-adrenoceptors. Eur J Pharmacol. 1996 Jan 4;295(1):69-73. [PubMed:8925876 ]
  3. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  4. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  5. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  6. Sleight AJ, Koek W, Bigg DC: Binding of antipsychotic drugs at alpha 1A- and alpha 1B-adrenoceptors: risperidone is selective for the alpha 1B-adrenoceptors. Eur J Pharmacol. 1993 Jul 20;238(2-3):407-10. [PubMed:7691623 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate c...
Gene Name:
HTR1D
Uniprot ID:
P28221
Molecular Weight:
41906.38 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  3. Schreiber S, Backer MM, Weizman R, Pick CG: Augmentation of opioid induced antinociception by the atypical antipsychotic drug risperidone in mice. Neurosci Lett. 1997 May 30;228(1):25-8. [PubMed:9197279 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistagonist
General Function:
Epinephrine binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phent...
Gene Name:
ADRA2B
Uniprot ID:
P18089
Molecular Weight:
49565.8 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Fenton C, Scott LJ: Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs. 2005;19(5):429-44. [PubMed:15907153 ]
  2. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
  2. Canton H, Verriele L, Millan MJ: Competitive antagonism of serotonin (5-HT)2C and 5-HT2A receptor-mediated phosphoinositide (PI) turnover by clozapine in the rat: a comparison to other antipsychotics. Neurosci Lett. 1994 Nov 7;181(1-2):65-8. [PubMed:7898773 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000 Nov 24;68(1):29-39. [PubMed:11132243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Keks NA, Culhane C: Risperidone (Risperdal): clinical experience with a new antipsychosis drug. Expert Opin Investig Drugs. 1999 Apr;8(4):443-52. [PubMed:15992090 ]
  2. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999 Feb;359(2):147-51. [PubMed:10048600 ]
  2. Hendset M, Molden E, Refsum H, Hermann M: Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol. 2009 Dec;29(6):537-41. doi: 10.1097/JCP.0b013e3181c17df0. [PubMed:19910717 ]
  3. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761-804. doi: 10.2165/11318070-000000000-00000. [PubMed:19902987 ]
  4. Zhou SF: Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. [PubMed:19817501 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Yasui-Furukori N, Hidestrand M, Spina E, Facciola G, Scordo MG, Tybring G: Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8. [PubMed:11560868 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  8. Source [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Fang J, Bourin M, Baker GB: Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999 Feb;359(2):147-51. [PubMed:10048600 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
  2. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 03:38